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Abstract
The opioid addiction epidemic is the most overwhelming public health
crisis our country has faced. It is now creating a legal crisis, as the its
poisonous fruits spill over into the criminal, tort, and family courts. The
epidemic costs the U.S. economy about $500 billion every year, and the
pressure is crippling our legal systems. This Article is an attempt to relieve
some of that pressure, by advocating for a comprehensive public health
campaign based upon a new model of addiction. Research shows that the
prevalent “moral choice” model of addiction has facilitated stigma and
discouraged treatment, by viewing affected individuals as blameworthy,
different in kind, and hopeless. Even when programs are accessible, which
they often are not, individuals will not seek treatment because they fear
adopting the label of “addict.” In this Article, I affirmatively reject the
moral choice model, identifying it as an obstacle to mitigating the opioid
epidemic. In its place, I offer a model of addiction that more closely tracks
its complex disease etiology, while humanizing people with addiction,
removing stigma, and encouraging treatment. I refer to this model as the
“integrated disease model,” or IDM, as it explains addiction as a neurogenetic phenomenon, but does not locate addiction entirely in the brain.
Rather, it places addiction on equal footing with other chronic diseases,
such as lung cancer or diabetes, each of which has significant genetic,
behavioral, and environmental causes. This Article will explain 1) how the
moral choice model leads to no treatment and poor treatment, 2) how the
law has furthered stigma through the criminalization of addiction, 3) and
why we need to fund a comprehensive public health campaign based upon
findings from neuro-genetics and public health. The IDM emphasizes the
biological continuum of genetic risk factors to which we are all susceptible,
the neurological networks that are impaired once the addiction has taken
hold, and finally, the incredible power of evidence-based treatments.
Explaining addiction in this way –as a treatable, complex disease—has been
shown to reduce stigma and encourage treatment.
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ADDICTION AS DISEASE
INTRODUCTION
A. The Problem of Addiction Stigma
Stigma is a powerful and multidimensional social force. It can be
based on visible markings like skin color or leprosy, or it can be based on
invisible characteristics such as being widowed or mentally ill. Essentially,
stigma is defined as labeling differences in others, then using those
differences to reduce someone from “whole and usual” to “tainted and
discounted.”1 Stigma must be understood with reference to a power
structure, as it reproduces inequities among under-privileged groups.2 Like
stereotyping, the process of stigmatization relies on sticky
overgeneralizations, which in turn are used to justify social exclusion,
prejudice, and discrimination.3 Stigma manifests in three distinct ways. It
first develops between members of a society through gossip and social
sanctions, then may become manifest in legal and social institutions such as
housing and employment, and eventually is internalized by those
stigmatized, leading to shame and reduced feelings of self-worth.4
Drug addiction is extraordinarily stigmatized. A comprehensive
study by the World Health Organization found that drug addiction ranked at
the top of a list eighteen stigmatized social problems.5 Among mental
illnesses, which as a group are quite stigmatized, drug addiction ranks as the
most stigmatized disorder, with lay people rating “addicts” as more
dangerous, less predictable, and more to blame for their disorders than
1
Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know;
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 3 (2013)
2
Laramie Smith, et al., Substance Use Stigma: reliability and validity of a theory-based scale for
substance-using populations 162 DRUG ALCOHOL DEPENDENCE 34, 36
3
National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, at p.4; (2016)
Washington, DC: The National Academies Press. doi: 10.17226/23442; available for download at
www.NAP.edu.
4
Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 275
(2017); National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, at p.4; (2016)
Washington, DC: The National Academies Press. doi: 10.17226/23442; available for download at
www.NAP.edu;
5
Robin Room, et al, “Cross-Cultural Views on Stigma Valuation Parity and Societal Attitudes
towards Disability,” in T.B. Üstün and S. Chatterji, eds., Disability and Culture: Universalism and
Diversity (Seattle: Hogrefe & Huber, 2001): 247–291; as cited in Daniel Buchman, et al., The
Epidemic as Stigma: The Bioethics of Opioids, 45 J. Law Med. And Ethics, 607, 607(2017).
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people with depression or schizophrenia.6 With blame comes moral
judgment.7
Because the word “addict” carries with it such negative
connotations, and conflates the disorder with the individual, the preferred
convention now is to refer to addicts as people with substance use disorder,
or SUD. Studies have shown that the way we talk about addiction matters,
and can exacerbate stigma.8 However, as this article is exploring the very
underpinnings of these negative connotations and the social response to the
label of “addict”, I will sometimes employ the non-clinical and stigmatized
terminology.
The predominant narrative of addiction holds that it is caused by a
weak character and immoral choices. Media portrayals rely on this model,
with ubiquitous stories of individual addicts who made bad decisions, broke
the law, and never obtained sobriety. This “moral choice” model has
facilitated stigma, by treating affected individuals as blameworthy, different
in kind, and hopeless. Coincidentally, these same attributes are frequently
used to dehumanize individuals, and to justify social distance, harsh
punishment and legal discrimination. Stigma associated with the moral
choice model has discouraged many people from getting treatment, as they
resist adopting the label of the “addict” even when their disorder is
advanced. Quite literally, stigma kills.9
As addiction manifests in socially undesirable behavior, judgment
toward people with SUD is understandably complicated. People with SUD
may deceive and manipulate to obtain drugs or hide use. Erecting healthy
boundaries with someone with SUD is not enacting stigma. This may be
necessary self-protection. We can, however, discourage the unhealthy and
antisocial behavior, without shaming the individual by helping these
individuals seek clinical treatment, and understanding that their decisions
are highly constrained by a powerful disease. Frankly, we must, rehumanize addiction by treating addiction like any other complex, and
6
M.C. Angermeyer and Sandra Dietrich, Public Beliefs about and Attitudes Towards People with
Mental Illness: a review of population studies, 113 Acta Psychiatr. Scand. 163, 170 (2006)
7
M.C. Angermeyer and Sandra Dietrich, Public Beliefs about and Attitudes Towards People with
Mental Illness: a review of population studies, 113 Acta Psychiatr. Scand. 163, 170 (2006):“[Our
research showed] that people addicted to drugs were viewed as significantly more responsible for
their disorder compared to people with mental illness or those in a wheelchair…blame [led to
perceptions] that they were most able to overcome it.”
8
For example, when physicians received a vignette that described the patient as a “substance abuser,”
as opposed to “someone with substance abuse disorder,” they were more likely to blame the
individual for his problem, and think he should be punished for not adhering to court-ordered
treatment. See, Harvard Mental Health Letter, Harvard In-brief, April 2010, available online at
http://www.health.harvard/edu/newsletter_article/addiction-terminology-affects-clinicisn-attitudestowards-patients.
9
Sarah Wakeman & Josiah Rich, Barriers to Medications for Addiction Treatment: How Stigma
Kills, 53 SUBSTANCE USE AND MISUSE 330, 330 (2018).
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chronic disease. Once addiction is properly conceived of as a disease, we
can then make sure that people with SUD have access to treatment, so they
can stop the cycle of antisocial behavior. Just as people with bipolar
disorder or depression may at times seem “selfish” or difficult to handle, we
should not use their untreated behavior as a justification for denying them
treatment.
In this Article, I affirmatively reject the moral choice model. In its
place, I offer a model of addiction that more closely tracks its disease
etiology, while humanizing people with addiction, removing stigma, and
encouraging treatment. I refer to this model as the integrated disease model,
or IDM, as it explains addiction as a neuro-genetic phenomenon, but does
not locate addiction entirely in the brain. Rather, it places addiction on
equal footing with other complex and chronic diseases, such as lung cancer,
or diabetes, which also have significant genetic, behavioral, and
environmental causes.10 Employing the IDM, I advocate for a massive, new,
federal public health campaign that uses neuro-genetic findings and stories
of recovery to demonstrate that people with addiction are not blameworthy,
not different in kind, and not hopeless.
By emphasizing that addiction is a disease, and thus prioritizing
prevention and treatment of affected individuals first and foremost, we can
hopefully reduce the unfair stigma that hinders recovery and leads to
antisocial behaviors. After clinical care is prioritized, we can then work on
social policies that promote inclusion, such as criminal justice reform and
fair housing and employment practices. But a key premise of this Article is
that we ought not “jump the gun” to focus on social determinants of health,
when we have not even adopted a model of addiction that prioritizes the
primary determinants of health.
This Article will thus proceed in four brief parts. In the first part, I
will provide evidence for the existence of stigma toward people with SUD,
and explain how it leads to no treatment and poor treatment. In the second
10
Lung cancer and diabetes can be caused by personal choices and behavior, such as smoking
cigarettes, eating too much sugar, or using intravenous needles. So too can addiction be caused in part
by voluntary choices to consume drugs. There are also genetic and biological vulnerabilities to lung
cancer and diabetes, just as there are with addiction, that can exacerbate risk and make conditions
worse. Given that Type 2 diabetes is sometimes caused by eating too many carbohydrates and sugars,
it remains stigmatized, even with its clear adoption as a medical disease. The IDM will not remove all
stigma. See generally, Jessica Browne, et al., ‘I call it the blame and shame disease’: a qualitative
study about perceptions of social stigma surrounding type 2 diabetes, 18 BMJ Open e003384
(2013)Without delving too far into the sociology of health, there are of course difficulties
distinguishing between an illness (where a person experiences symptoms) a disease (where someone
calls for professional help) and a sickness (where the person adopts the social role of patient).
However, the disease model is used as a heuristic to explain a medically-oriented model, that
encourages reflection on the biological and environmental causes of disease. See, AnnaHenrikje Seidlein and Sabine Salloch, Illness and disease: an empirical-ethical viewpoint, 20 BMC
MEDICAL ETHICS 5, 5 (2019)
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part, I will explain the law’s role in furthering stigma through the
criminalization of addiction, and our ineffective efforts to reduce stigma
through statutes like the Americans with Disabilities Act. In the third
section, I will explain competing models of addiction, providing evidence
for a disease model based on neuro-genetic causes and effects. In the fourth
section, I conclude with my recommendation for a new public health
campaign, based upon the IDM and the neuro-genetic risks of addiction. As
compared to previous models of addiction, which have focused attention
either exclusively on choice or the brain, this model incorporates aspects of
both to treat addiction like other chronic diseases. Employing the IDM, I
advocate for a massive, new, federal public health campaign that uses
neuro-genetic findings and stories of recovery to demonstrate that people
with addiction are not blameworthy, not different in kind, and not hopeless.
B. Why This Matters: The Opioid Crisis is a Public Health
Emergency
At the same time as physicians were recognizing rampant undertreatment of pain, pharmaceutical companies in the 1990s began
aggressively marketing new opioid medications that they claimed were
unlikely to be abused.11 This proved to be fatally, fraudulently, wrong.12
Consumption of oxycodone increased by a whopping 500% from 1999 to
2011, and opioid-related overdoses almost quadrupled.13 The alarming
increase in opioid use has led to the “worst drug overdose epidemic in [US]
history,” according to the Centers for Disease Control.14
Overdose deaths from opioids have led to an absolute decline in life
expectancy in the United States, and it is the number one cause of
accidental death.15 In 2016, the overdose death rate from synthetic opioids
doubled from the last year, likely driven by an influx of potent, non11

Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health
Tragedy, 99 AM. J. PUBLIC HEALTH 221, 223 (2009)
“A consistent feature in [Purdue Pharmaceutical’s] promotion and marketing of OxyContin was a
systematic effort to minimize the risk of addiction in the use of opioids for the treatment of chronic
non–cancer-related pain.”
12
Art Van Zee, The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health
Tragedy, 99 AM. J. PUBLIC HEALTH 221, 223 (2009)
“A consistent feature in [Purdue Pharmaceutical’s] promotion and marketing of OxyContin was a
systematic effort to minimize the risk of addiction in the use of opioids for the treatment of chronic
non–cancer-related pain.”
13
Andrew Kolodny, et al., The Prescription Opioid and Heroin Crisis: A Public Health Approach to
an Epidemic of Addiction, 36 ANNUAL REVIEW OF PUBLIC HEALTH 559, 559 (2015).
14
Andrew Kolodny, et al., The Prescription Opioid and Heroin Crisis: A Public Health Approach to
an Epidemic of Addiction, 36 ANNUAL REVIEW OF PUBLIC HEALTH 559, 559 (2015).
15
Peter Muenning, et al., America’s Declining Well-Being, Health, and Life Expectancy: Not Just a
White Problem, 108 AM. J. PUBLIC HEALTH 1626, 1626 (2018)
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prescription fentanyl from China.16 More than a hundred people continue to
die from the epidemic every day17. This has led the Department of Health
and Human Services and the President of the United States to declare our
modern addiction crisis a “public health emergency.”18
The opioid crisis has exposed a devastating reality: with the right
combination of environmental stress19 and genetic vulnerability20, any of us
could become addicted to drugs. Any of us could start taking OxyContin for
kidney stones or a sports injury, and end up living on the streets after our
family has kicked us out. Any of us could die of a heroin or fentanyl
overdose. A big part of what separates those who become addicted from
those who do not is something entirely outside of our control: our genes.
Many who have been touched by the opioid crisis now appreciate
that anyone can become addicted, regardless of race or socio-economic
status. However, stigma is still felt by people with opioid use disorder
(OUD), and disproportionately so for those from lower social classes.
Indeed, social class is a better predictor of adverse outcomes from addiction
then the patterns or volume of drug use itself.21 While people who
experience childhood trauma are at an increased risk of developing SUD22,
addiction is still addiction when it manifests. And it is still largely viewed
as a disease of the morally bankrupt or the weak-willed. We see this in the
16
See, Centers for Disease Control Newsroom, U.S. drug overdose deaths continue to rise;
increase fueled by synthetic opioids, March 29, 2018, available online at
https://www.cdc.gov/media/releases/2018/p0329-drug-overdose-deaths.html. (“Across demographic
categories, the largest increase in opioid overdose death rates was in males between the ages of 2544.”); see also, Colleen Barry, Fentanyl and the Evolving Opioid Epidemic: what strategies should
policy makers consider? 69 PSYCHIAT. SERV. 100, 100 (2018) (encouraging a public health messaging
campaign that educates on the risks of fentanyl).
17
Health and Human Services, What is the U.S. Opioid Epidemic?,
HTTPS://WWW.HHS.GOV/OPIOIDS/ABOUT-THE-EPIDEMIC/INDEX.HTML, UPDATED JAN. 2019
18
“On October 26, 2017, President Trump announced that his Administration was declaring the
opioid crisis a national Public Health Emergency under federal law, effective immediately. ‘I am
directing all executive agencies to use every appropriate emergency authority to fight the opioid
crisis,’ the President said.” See, The White House, The Opioid Crisis, available online
https://www.whitehouse.gov/opioids/
19
Shelly Wiechelt & Shulamith Lala A. Straussner, Introduction to the Special Issue: Examining the
Relationship Between Trauma and Addiction 15 J. SOCIAL WORK PRACTICE IN THE ADDICTIONS 1, 1
(2015) (“Furthermore, it is empirically well established that there is a link between trauma-related
disorders and sub- stance use disorders.”) See also, Annett Lotzin, et al., Profiles of Childhood
Trauma in Patients with Alcohol Dependence and Their Associations with Addiction-Related
Problems, 40 ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH 543, 543 (2016)“The high
occurrence of childhood trauma in individuals with alcohol dependence is well-recognized.”
20
Nora D. Volkow and A. Thomas McLellan, Opioid Abuse in Chronic Pain — Misconceptions
and Mitigation Strategies 374 NEW ENGL. J. MED. 1253, 1257 (2016)
21
Robin Room, Stigma, Social Inequality and Alcohol and Drug Use, 24 DRUG AND ALCOHOL
REVIEW 143, 143 (2005)
22
Shelly Wiechelt & Shulamith Lala A. Straussner, Introduction to the Special Issue: Examining
the Relationship Between Trauma and Addiction 15 J. SOCIAL WORK PRACTICE IN THE ADDICTIONS 1,
1 (2015)
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way that people think addiction should be treated, which is often through
peer-counseling, jail time, and cold-turkey abstinence, rather than through a
health care clinic.23
I.

EVIDENCE OF ADDICTION STIGMA

It is perhaps no surprise that people with SUD are extensively
stigmatized. However, the extent of the stigma is a bit astounding.
Widespread stigma presents at the social, structural, and personal levels. In
this section I will analyze the evidence for each. Given how frequently
people hold stigmatized views of addicts, and how this leads to massive
under-treatment, it is disconcerting that fewer than ten experimental studies
exist on SUD stigma24. Despite the clear evidence we have of the existence
of stigma from observational studies and surveys, more empirical research
needs to be done on how best to mitigate it.
a. Social Stigma
Americans report wanting considerable social distance from people
with SUD. People with SUD are rated as having little social value, and
therefore it is considered acceptable not to help them, and to exclude them
from social spaces.25 For example, 75% of Americans are unwilling to have
someone with drug dependence move next door to them.26 Nearly 60% of
Americans would be unwilling to make friends with someone with “drug
dependence,” and nearly 73% would be unwilling to even spend one
evening socializing with an addict.27 Let that sink in. Given this extreme
desire for social distance, it is no wonder that 90% of respondents say they
are unwilling to have someone with drug dependence marry into their
family. Seventy-eight percent say they are unwilling to have someone with
23

See, Barbara Andraka-Christou, America Needs the Treat Act: Expanding Access to Effective
Medication for Treating Addiction, 26 HEALTH MATRIX 309, 335 (2016).National Academies of
Science, Ending Discrimination Against People with Mental and Substance Use Disorders: The
Evidence for Stigma Change, available for download at http://nap.edu/23442, at p. 1
24
Patrick Corrigan & Katherine Nieweglowski, Stigma and the public health agenda for the opioid
crisis in America, 59 INTL. J. OF DRUG POLICY 44, 44 (2018)
25
Patrick Corrigan, et al., The Public Stigma of Mental Illness and Drug Addiction: Findings from a
Stratified Random Sample, 9 J. SOC. WORK 139, 139 (2009); see also Kumiko Yoshioko, et al.,
Associations between Beliefs about the Causes of Mental Disorders and Stigmatizing Attitudes:
Results of a Mental Health Literacy and Stigma Survey of the Japanese Public, 45 INT. J. MENTAL
HEALTH 183, 183 (2016); Shuntaro Ando et al, Review of mental-health-related stigma in Japan, 67
PSYCH CLIN. NEUROSCI. 471, 471 (2013)
26
Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know;
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 9 (2013)
27
Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know;
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 9 (2013)
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drug dependence work closely with them on their job.28 These levels of
stigmatizing attitudes are quite a bit higher than for people with depression
or schizophrenia.29
The little research on stigma that is specific to OUD reveals that the
stigma persists in the face of our recent crisis. Many thought that stigma
might be lessened. Unlike heroin or cocaine, which are illegal, OUD could
have begun with a valid prescription from a doctor, even if the pills were
later diverted to someone without a prescription. Some thought this might
reduce the moral judgment against people with OUD, given its ambiguous
legal status.30 It was also thought that because the people affected by OUD
were more likely to be white, wealthy, and have insurance, compared to
those impacted by the previous addiction crises (such as the cocaine
epidemic of the 1980s and 90s), people may have less stigmatizing attitudes
toward them.
So far, this has not turned out to be the case. The prevalence of
OUD is not decreasing many forms of stigma. Respondents with personal
experience with someone with OUD were more likely to say that 1) people
with OUD are to blame for their disorder, 2) some people lack the selfdiscipline to use pain medications responsibly, and 3) and employers and
landlords should be allowed to deny employment or housing to people with
OUD.31 Fewer people are unwilling to have someone with OUD work
closely with them (59%) or marry into the family (66%), compared to
previous studies of drug addiction generally.32 However, the desire for
social distance remains quite high in the general population, and in some
cases is slightly higher for people who have personal experience with
someone with OUD. Greater exposure to people with SUD is not going to
be the silver-bullet to reducing stigma. This might be due to the
manipulative behavior that these friends have experienced. They are not
discriminating based upon ignorance of addiction; they are discriminating
based upon perceived behavior. This must be addressed at the systemic
level, by creating effective treatments and improving access to them, and by
removing the stigma associated with being someone with SUD.
Most Americans believe that people with SUD are dangerous and
28

Colleen Barry, et al, Stigma, Discrimination, Treatment Effectiveness, and Policy: Public Views
about Drug Addiction and Mental Illness, 65 Psych. Serv. 1271 (2014)
29
Bernice Pescosolido, The Public Stigma of Mental Illness: What do we think; what do we know;
what can we prove? 54 J. HEALTH AND SOCIAL BEHAVIOR 1, 9 (2013)
30
Kennedy-Hendricks, et al, 68 Psychiatric Serv.462 (2017)
31
Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid
Use Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies,
68 PSYCHIATRIC SERV. 462 (2017)
32
Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid Use
Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies,
68 PSYCHIATRIC SERV. 462, 466 (2017)
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unpredictable.33 Despite evidence that people with SUD are more likely to
injure themselves, many Americans believe that persons with alcohol or
drug addiction are more likely to be violent toward others.34 This is likely
due to the depiction of people with drug addiction in the mass media and
popular culture.
Our knowledge about persons with addictions is shaped through the
“visible, marginalized street populations of persons with addictions, or
through stereotypes of persons with addictions as portrayed in movies.”35
Unfortunately, people with SUD are represented in film in stereotypical
ways that do not reflect their diverse lives.36 Society has become inured to
viewing portrayals of untreated people with SUD as “disheveled, often
homeless, and potentially dangerous.”37 We need to depict people with
SUD in more mainstream, and diverse, ways.38
Individuals with substance use disorders elicit great social distance
across all stakeholders. The public, family members, and even health care
providers hold stigmatizing views of addicts. Most these groups think that
people with SUD are not trustworthy, tend to be aggressive, and tend to be
criminal.39 Even drug users themselves stigmatize the route of drug
administration, with intravenous drug users being considered dirtier and
worse off than those who abuse oral pain medications.40
The stigma that health care providers feel toward people with SUD
is well-documented. When physicians hold beliefs about the causes of
addiction that are stigmatizing and moralizing, this creates significant
barriers to people with SUD obtaining adequate treatment.41 Not only are
33
M.C. Angermeyer and Sandra Dietrich, Public Beliefs about and Attitudes Towards People with
Mental Illness: a review of population studies, 113 ACTA PSYCHIATR. SCAND. 163, 169 (2006)
34
Bernice Pescosolido, et al., “A Disease Like Any Other,” A decade of change in public reactions to
schizophrenia, depression, and alcohol dependence, 167 AM. J. PSYCH. 1321, 1321 (2010); see also
CL Barry, et al, After Newtown—public opinion on gun policy and mental illness, 368 NEW ENGLAND
J. MED. 1077 (2013);
35
Anne Marie Lavack, Using social marketing to de-stigmatize addictions: A review, 15 ADDICTION
IN RESEARCH AND THEORY, 479, *3 (2007)
36
Anne Marie Lavack, Using social marketing to de-stigmatize addictions: A review, 15
ADDICTION IN RESEARCH AND THEORY, 479, *3 (2007)
37
Colleen Barry, et al., Stigma, Discrimination, Treatment Effectiveness, and Policy: Public Views
About Drug Addiction and Mental Illness, 65 PSYCHIATRIC SERVICES 1269, 1272 (2014)
38
Patrick Corrigan, Karina J. Powell, and Patrick J. Michaels, The Effects of News Stories on the
Stigma of Mental Illness, 201 JOURNAL OF NERVOUS AND MENTAL DISEASE 179, 181 (2013)
39
Leonieke C van Boekel, et al., Comparing stigmatising attitudes towards people with substance
use disorders between the general public, GPs, mental health and addiction specialists and clients, 61
Int. J of Social Psychiatry, 539, 544 (2014).
40
Peter Flom, et al., Stigmatized drug use, sexual partner concurrency, and other sex risk network
and behavior characteristics of 18 to 24-year-old youth in a high-risk neighborhood, 28 SEXUALLY
TRANSMITTED DISEASES, 598 (2001)
41
Katharine Press, et al., What Patients with Addiction Disorders Need from their Primary Care
Physicians: a qualitative study, 32 SUBSTANCE ABUSE 349-355 (2016); Moira Ray, et al., Patient and
Provider Comfort Discussing Substance Abuse, 45 FAMILY MEDICINE 109 (2013); see also Leonieke
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patients less likely to seek care because they feel judged or ashamed, these
physicians might ignore addiction risk factors due to personal discomfort
with the disorder. Additionally, patients will not be completely honest with
their providers when they perceive these moralized and judgmental
beliefs.42 This will lead to under-treatment or inappropriate treatments.
b. Structural Stigma
Structural stigma is manifest by public and private actors, including
judges, prosecutors, legislators, social services, banks, insurance companies,
restaurants, schools, and clubs. Stigma at the structural level appears as an
endorsement of discrimination, which contributes to public and selfstigma.43 Structural stigma places unfair limits on someone’s exercising
their civil rights due to the label of addict, rather than being based on any
observable behavior. Examples include “discriminatory legislation that
places restrictions on jury service, voting, holding political office, and
parental custody rights”44 as well as discriminatory hiring or admissions
policies based on stereotypes.”45 It also includes the lack of parity between
insurance coverage for addiction treatment and other forms of medical
treatment.46 It remains too soon to tell whether federal parity is helping to
increase treatment and reduce stigma,47 but there continue to be many
C van Boekel, et al., Comparing stigmatising attitudes towards people with substance use disorders
between the general public, GPs, mental health and addiction specialists and clients, 61 Int. J of
Social Psychiatry, 539, 544 (2014).
42
Lily Frank and Saskia Nagel, Addiction and Moralization: the role of the underlying model of
addiction, 10 NEUROETHICS 129, 133 (2017)
43
National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, Summary at
p.4-5; (2016) Washington, DC: The National Academies Press. doi: 10.17226/23442; available for
download at www.NAP.edu.
44
National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, Research
Stragegies, at p.105; (2016) Washington, DC: The National Academies Press. doi: 10.17226/23442;
available for download at www.NAP.edu
45
National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, Summary at
p.4-5; (2016) Washington, DC: The National Academies Press. doi: 10.17226/23442; available for
download at www.NAP.edu.
46
“One reason for this lack of parity between medical care and addiction services may be stigma; if
addiction disorders are perceived as the fault of the addicted and not worthy of treatment, then
regulators and the public will be less likely to press for equal coverage.” See, Valarie K. Blake,
Engaging Health Insurers in the War on Prescription Painkillers, 11 HARV. L. & POL'Y REV. 485,
501 (2017)
47
Colleen Barry, Howard Goldman, Haiden Huskamp, Federal Parity In The Evolving Mental
Health And Addiction Care Landscape, 35 HEALTH AFFAIRS, 1009, 1015 (2016) (“[T]he incentives
for health plans to avoid adverse selection do not go away in the presence of federal parity, since
there will still be variation across plans with respect to the generosity of the mental health and substance use disorder benefits offered. The next five years will be critical to gaining a detailed picture
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aspects of the delivery of addiction treatment that are less accessible and
inferior to regular medical care.48
Stigma has far-reaching effects, and impacts how people think about
addressing SUD as a social problem. For example, 43% of respondents say
they are opposed to individuals with drug addiction receiving equivalent
insurance benefits, with 49% opposed to increased government spending on
treatment and a whopping 76% opposed to increased government spending
on housing.49 These percentages are much higher than those for mental
illness generally, and have been tied to stigma.
The fact that people with SUD are overrepresented in the criminal
justice system, is both a consequence and a source of structural stigma.50 In
a large study of attitudes toward people with OUD, higher levels of stigma
were associated with greater support for punitive policies.51 These punitive
policies included greater criminalization, and permission to discriminate in
housing and employment. Those who held greater stigmatized views of
SUD also had lower support for public health-oriented policies like
demanding insurance parity between physical and mental health services,
and improving treatment access and harm reduction strategies.52
c.

Self-Stigma
Self-stigma includes negative views that stigmatized individuals
believe others think about them. It also refers to negative thoughts and
shame that emerge from identification with a stigmatized group.53 At the
personal level, most, but not all, individuals with SUD feel considerable
shame for their disorder. This is probably due in part to a feeling that they
are failing in exercising agency, and in “letting ourselves down we typically
let down others who rely on us.”54 Despite this internally focused shame,
of the extent to which parity is improving the health and well-being of people diagnosed with a
mental health or substance use disorder, and to better assessing what new policies are needed to build
on the Wellstone-Domenici law’s achievements.”)
48
Corey Davis, et al., Action, Not Rhetoric, Needed to Reverse the Opioid Overdose Epidemic, 45 J.
LAW, MED. & ETHICS 20, 21 (2017) (describing lack of access to evidence-based treatment, and
under-enforcement of the Mental Health Parity and Addiction Equity Act.)
49
Colleen Barry, et al, Stigma, Discrimination, Treatment Effectiveness, and Policy: Public Views
about Drug Addiction and Mental Illness, 65 PSYCH. SERV. 1271 (2014)
50
National Academies of Sciences, Engineering, and Medicine, Ending Discrimination Against
People with Mental and Substance Use Disorders: The Evidence for Stigma Change, at p.4; (2016)
Washington, DC: The National Academies Press. doi: 10.17226/23442; available for download at
www.NAP.edu.
51
C Dackis and C O”Brien, Neurobiology of Addiction: treatment and public policy ramifications, 8
NATURE NEUROSCIENCE 1431,1431 (2008)
52
Kennedy-Hendricks, et al, 68 Psychiatric Serv.462 (2017)
53
van Brakel et al., 2006
54
Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276
(2017);
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there is certainly a component that is also caused by the external, social
stigma that people with SUD experience.55 Perceptions of public stigma
feed into normative self-concepts, so that people with SUD tend to have
reduced self-esteem56. The common representation of addicts as unreliable
or untrustworthy, for example, can make affected individuals feel excluded
from the public sphere, and lead them to see themselves as deserving of this
shunning treatment.57 They then might withdraw from society, and stop
seeking employment and participating in their communities in healthy
ways. And most importantly, they will then be motivated to continue to
consume drugs or alcohol to reduce the negative feelings that stem from
their shame. This is what some researchers have dubbed the “looping
effect,” as the label of “addict” can feed back into negative behavior, that
then reinforces the negative judgments around the label.58
It is possible to separate shame from blame. Many of us experience
shame for things that are not socially blameworthy or immoral (such as
having a physical disability). This is particularly acute if the stigmatized
condition makes others worried that we are contagious or they experience
disgust at the sight of us. But the truth is that when personal shame is
experienced as part of social stigma for a behavior that is viewed rightly or
wrongly as immoral, then the emotion of shame immediately stimulates
feelings of moral failure.59
Research on self-stigma in OUD has demonstrated that the higher
the self-stigma, the higher the rates of depression for affected individuals.60
Additionally, people who reported recent injection drug use have been
found to have significantly higher mean scores on validated measures of

55
Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 275
(2017);
56
Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276
(2017);
57
Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276
(2017);
58
Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 278
(2017);
59

Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 276
(2017);
60

Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification,
12 J ADDICT MED. 19–23 (2018); “General Self-Stigma Subscale scores were associated positively
and significantly with PHQ-2 depression (r = 0.36, p < .001) as were Treatment Stigma Subscale
scores (r = 0.14, p = 0.004).”
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self-stigma.61 And individuals who reported having accessed detoxification
care had higher rates of self-stigma than those who had not, which the
researchers believed was due to a feeling that their treatments had failed.62
Interestingly, this same study found that the self-stigma ratings were higher
for wealthier people with higher levels of education.63 Perhaps within this
group they feel like they have more social value to lose, and are therefore
more afraid of adopting the label of addict, or acknowledging their
substance use disorder.
People with SUD exhibit stigmatized views toward people with
more “severe” forms of the disorder. For example, one study found that
people abusing pain meds “held stigmatising attitudes towards those who
used heroin, with employment, education and appearance listed as reasons
why people who used codeine were more ‘respectable’”.64 Another
qualitative study of people in treatment for over-the-counter codeine
dependence in Australia found there were perceptions that MAT was for
“drug users”, and was for “other people”, namely those using intravenous
heroin.65 Even among people with drug addiction, there is a hierarchy of
shame and othering of those more severely affected.
2. Stigma Leads to No Treatment and Poor Treatment
Public health messaging from the last several decades has focused
on instilling fear in children—painting a terrible picture of addicts as dirty,
pathetic, dishonest, and homeless. While these campaigns may have worked
in the past, they are now backfiring. The popular construction of the addict
as a dangerous, unpredictable criminal has led to massive under-treatment.
While more than 2.3 million people in the U.S. have an opioid use disorder,
less than 40% receive evidence-based treatment.66 The reason in part, lies
61

Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification,
12 J ADDICT MED. 19, *4 (2018).
62
Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification,
12 J ADDICT MED. 19, *6 (2018).
63
Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification,
12 J ADDICT MED. 19, *6 (2018).
64
Sasha Cooper, et al., Perceived stigma and social support in treatment for pharmaceutical opioid
dependence, 37 DRUG & ALCOHOL REVIEW 262, 263 (2018)
65

Suzanne Nielsen, et al., Pharmaceutical opioid analgesic and heroin dependence: How do
treatment-seeking clients differ in Australia?, 30 DRUG AND ALCOHOL REVIEW 291, 297 (2011)
(“There may be societal elements at play, such as the reported perception that opioid substitution
treatments—of which the majority of participants in this study were recruited from—are primarily for
‘drug users’, specifically heroin users.”)
66
Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S230 (2018)
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with stigma. Stigma is routinely among the most common reasons people
with SUD give for not initiating treatment or maintaining treatments that
allow for sustained abstinence.67 Stigma has been labeled “the most
important obstacle to the provision of mental health care.”68 As such, the
U.S. Substance Abuse and Mental Health Services Administration
(“SAMHSA”) prioritizes reducing stigma, as it is an essential barrier to
treatment and public health goals.69 Stigma discourages affected individual
from seeking treatment, as they do not want to adopt the label of an
“addict.”70 Stigma also increases shame which might perpetuate substance
use,71 discourages their health care providers from treating them adequately,
72
and makes insurance coverage less accessible and more expensive.73
Even if someone can overcome the many hurdles to receiving adequate
addiction treatment, stigma is still associated with negative mental and
physical health consequences.74
Not only does stigma provide a reason for denying the disorder and
not accessing treatment, but it also impacts the quality of the treatment that
people with SUD receive. A 2015 public opinion survey found that only
67

Sara Wallhed Finn, Ann-Sofie Bakshi & Sven Andreasson, Alcohol consumption, dependence, and
treatment barriers: perceptions among nontreatment seekers with alcohol dependence, 49
SUBSTANCE USE MISUSE, 762, 762 (2014); Charlotte Probst, et al., Alcohol use disorder severity and
reported reasons not to seek treatment: a cross-sectional study in European primary care practices,
10 Substance Abuse Treatment, Prevention, and Policy (2015) (“Of 1,008 patients diagnosed with an
alcohol use disorder (via general practitioner or patient interview) in the past 12 months, the majority
(N = 810) did not receive treatment and 251 of those gave a reason for not seeking treatment. The
most frequent reason was ‘lack of problem awareness’ (55.3 % of those who responded), the second
most common response was ‘stigma or shame’ (28.6 %), followed by ‘encounter barriers’ (22.8 %)
and ‘cope alone’ (20.9 %)”).
68
NORMAN SARTORIUS, FIGHTING STIGMA: THEORY AND PRACTICE, 1 World Psychiatry 26, 27 (2002)
69
Patrick Corrigan & Katherine Nieweglowski, Stigma and the public health agenda for the opioid
crisis in America 59 INT. J. DRUG POLICY 44, 44 (2018)
70
Laramie Smith, et al., Substance Use Stigma: reliability and validity of a theory-based scale for
substance-using populations 162 DRUG ALCOHOL DEPENDENCE 34, 36; C Erikson, The Science of
Addiction: From Neurobiology to Treatment, New York, New York, W.W. Norton Press (2007), at p.
3; Laura Williamson, Destigmatizing Alcohol Dependence: the requirement for ethical (not only
medical) remedy, 102 AMERICAN J. OF PUBLIC HEALTH e5, e6 (2012)
71
[cite]
72
LEONIEKE VAN BOEKEL, ET AL., STIGMA AMONG HEALTH PROFESSIONALS TOWARDS PATIENTS WITH
SUBSTANCE USE DISORDERS AND ITS CONSEQUENCES FOR HEALTHCARE DELIVERY: SYSTEMATIC REVIEW, 131
Drug and Alcohol Dependence 23, 23 (2013); MUKHERJEE R, ET AL, THE STIGMATISATION OF
PSYCHIATRIC ILLNESS: THE ATTITUDES OF MEDICAL STUDENTS AND DOCTORS IN A LONDON TEACHING
HOSPITAL, 26 PSYCHIATR BULL 178-181 (2002) (MORE THAN 50% OF CLINICIANS FELT PATIENTS WITH
SCHIZOPHRENIA, AND DRUG AND ALCOHOL ADDICTION WERE DANGEROUS, UNPREDICTABLE.)
73
“Historically, insurers have not funded addiction treatment as generously as other costly medical
services like cardiac care or organ transplant. Addicted patients were sometimes excluded from
enrollment in insurance or charged very high premiums. Some insurers also opted not to cover
addiction services, or pushed the costs of these services back onto patients through very high copays.” See, Valarie K. Blake, Engaging Health Insurers in the War on Prescription Painkillers, 11
HARV. L. & POL'Y REV. 485, 501 (2017)
74
Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification,
12 J ADDICT MED. 19–23 (2018)
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19% of Americans surveyed thought medication assisted treatment
(MAT)—the gold standard for opioid use disorder treatment —was the best
way to treat heroin dependence, preferring strategies like Narcotics
Anonymous that involve being “drug free.”75 At least 2.3 million people in
the U.S. have OUD, yet over 60% do not receive evidence-based
treatment.76 Only 4% of licensed MDs are approved to prescribe
buprenorphine, an effective drug that helps curb cravings for opioids and
withdrawal symptoms.77 Of over 14,000 drug treatment programs in the US,
some funded by federal block grants to states, most are not staffed with a
single licensed medical practitioner.78 If addiction were instead conceived
of as a medical disease, would we see these abysmal levels of evidencebased treatment?
Take for example, provider’s feelings toward Naloxone. Naloxone is
a short-acting mu-opioid antagonist that can be injected by emergency
responders who encounter someone who has recently overdosed. It quickly
reverses the acute effects of a drug overdose, such as respiratory
depression.79 Despite its ability to save lives, research suggests that
providers have generally negative attitudes about its use. The reasons for
these attitudes include concerns about “promoting or condoning substance
use,” the unsafe disposal of needles, and their feelings of frustration,
futility, and powerlessness.80 The latter is likely due to the drug’s ability to
stop this overdose, while doing nothing to prevent the next one.
Buprenorphine and methadone are the drugs that helps with that problem,
but they are also woefully under-prescribed.
Unfortunately, some providers and the public view MAT as
problematic, as you are “substituting one opioid for another.”81 Part of the
trouble may be with the mixed message behind the label itself, as
“Medication-Assisted Treatment” communicates that 1) medication is not
75
Bertha Madras, The surge of opioid use, addiction, and overdoses: responsibility and response of
the US health care system. 74 JAMA PSYCHIATRY 441, 441 (2017)
76
Nikki Bozinoff, et al, Correlates of Stigma Severity Among Persons Seeking Opioid Detoxification,
12 J ADDICT MED. 19–23 (2018): (“There are efficacious treatments for opioid use disorder (OUD),
however according to the National Survey on Drug Use and Health, of the 2.5 million Americans 12
years and older who misused or were dependent on opioids in 2012, fewer than 1 million received
treatment with methadone, buprenorphine/ naloxone or naltrexone.”)
77
Haffajee, et al., 54 Am. J. Prev. Med. S230 (2018)
78
Bertha Madras, The surge of opioid use, addiction, and overdoses: responsibility and response of
the US health care system. 74 JAMA PSYCHIATRY 441, 441 (2017)
79
NANCY HAUG, ET AL., ASSESSMENT OF PROVIDER ATTITUDES TOWARD #NALOXONE ON TWITTER, 37
Substance Abuse 35, 35 (2016)
80
NANCY HAUG, ET AL., ASSESSMENT OF PROVIDER ATTITUDES TOWARD #NALOXONE ON TWITTER, 37
SUBSTANCE ABUSE 35, 35 (2016)
81
Lloyd I. Sederer and Leslie A. Marino, Ending the Opioid Epidemic by Changing the Culture, 89
PSYCHIATRIC QUARTERLY 891, 892 (2018)
“In 2017, former Health and Human Services Secretary Tom Price was quoted as saying ‘If we’re
just substituting one opioid for another, we’re not moving the dial much.’”
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the primary treatment for SUD, 2) another, unnamed treatment is.82
Consider, the implications for example, of referring to an insulin
prescription for diabetes as “Medication-Assisted Treatment.” This label of
course begs the question—is there any other treatment that is not medical?83
Opioid agonists such as methadone or buprenorphine, two common
forms of MAT, are effective at reducing drug relapse, as they can mitigate
painful withdrawal and cravings that might fuel the addiction cycle.84 They
do so by releasing a sustained and small dose of opioids. Without MAT, the
immediate withdrawal symptoms, such as sweating, shaking, and diarrhea,
may resolve within a few days.85 Other symptoms, however, such as
dysphoria, insomnia, and anxiety can linger for months, and drive drug use
to self-medicate the withdrawal.86 These drugs literally save lives. They
should be prioritized for what they are—effective medical treatments.
For individuals with OUD, more than 80% return to drug use if
treated with only behavioral interventions, like Narcotics-Anonymous or
psychotherapy.87 In contrast, treatment with adequately dosed MAT leads to
only 15% of those treated continuing to use illicit opioids. 88 Buprenorphine,
in particular, “has demonstrated effectiveness in increasing treatment
retention, reducing opioid use, reducing mortality, and reducing the
transmission of HIV and hepatitis C,” and it has some cost, efficacy, and
administering advantages over methadone, especially when combined with
Naloxone.89 Because buprenorphine can be delivered in non-specialty
settings sublingually, or via injection or implant, it can be “less stigmatizing
for patients, better integrated with other medical care, maintained under a
82

Sean Robinson and Bryon Adinoff, The Mixed Message Behind ‘Medication-Assisted Treatment’
for Substance Use Disorder, 44 AMERICAN J. OF DRUG AND ALCOHOL ABUSE, 147, 148 (2018)
83
Sean Robinson and Bryon Adinoff, The Mixed Message Behind ‘Medication-Assisted Treatment’
for Substance Use Disorder, 44 AMERICAN J. OF DRUG AND ALCOHOL ABUSE, 147, 148 (2018)
84
Valerie Hewell, Angel Vasquez, & Inna Rivkin, Systemic and individual factors in the
buprenorphine treatment-seeking process: a qualitative study, 12 SUBSTANCE ABUSE TREATMENT,
PREVENTION, AND POLICY 1, 4-5 (2017) (As one person with OUD commented: “(Withdrawal) was
physical, mental, emotional, spiritual. I was a disaster for like…I think I made it…four days, and then
I went back.” Participants reported withdrawal made it challenging to quit or stay off opioids without
support. As one participant noted, “So I had to come off of it cold turkey, and it was a terrible,
terrible experience, so I just went back to heroin.” As such, participants described MAT as being
helpful in decreasing withdrawal symptoms, which allowed it to be used as a ‘stepping stone’ to
recovery”)
85
Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating
Addiction Vulnerability, 5 F1000 RESEARCH 1748, 1748 (2016)
86
Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating
Addiction Vulnerability, 5 F1000 RESEARCH 1748, 1748 (2016)
87
Sarah E. Wakeman,Using Science to Battle Stigma in Addressing the Opioid Epidemic: Opioid
Agonist Therapy Saves Lives, 129 AM. J. MED. 455, 455 (2016)
88
Sarah E. Wakeman,Using Science to Battle Stigma in Addressing the Opioid Epidemic: Opioid
Agonist Therapy Saves Lives, 129 AM. J. MED. 455, 455 (2016)
89
Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S232 (2018)
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long-term primary care–patient relationship, and available to special
populations” such as people in prison or on parole.90 Despite its
demonstrated clinical effectiveness, because buprenorphine contains small
amounts of opioids, many physicians and the public stigmatize its use, even
calling into question whether someone treated with physician-prescribed
buprenorphine can be considered in recovery, or sober.91
This is a dangerous perspective. Stigma surrounding MAT, and “the
belief that people on MAT were still addicts and not in the recovery
process,” has interfered with participants’ treatment and recovery.92 Why is
MAT not respected? Because addiction is not seen as a disease. We treat
lung cancer with chemotherapy toxins and radiation, realizing that these
dangerous treatments would not be prescribed to someone without cancer.
We should treat MAT in the same way we treat other treatment options, by
prescribing it when its clinical benefits outweigh its risks. In many cases,
when confronted with continued intravenous drug use and risk of overdose,
the risks are easily justified.
Recognizing the barriers to accessing MAT, Congress passed the
Drug Addiction Treatment Act in 2000 (“DATA 2000”), allowing
physicians to request a waiver from the Controlled Substances Act
requirements to treat OUD outside of a federally-regulated Opioid
Treatment Program (“OTP”).93 Even still, however, fewer than 4% of
licensed physicians are approved to prescribe buprenorphine.94 It is
90

Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S233 (2018)
91
One patient in recovery through MAT explained the stigma toward buprenorphine this way: “I hear
it all the time: ‘you’re not sober’. And it really hurts my feelings because I worked hard…from where
I was to where I (am) now…I got my own place, I got my disability, I got everything on track. And all
she said was, ‘you’re still not sober.’” Valerie Hewell, Angel Vasquez, & Inna Rivkin, Systemic and
individual factors in the buprenorphine treatment-seeking process: a qualitative study, 12 SUBSTANCE
ABUSE TREATMENT, PREVENTION, AND POLICY 1, 4-5 (2017) see also, Barbara Andraka-Christou,
America Needs the Treat Act: Expanding Access to Effective Medication for Treating Addiction, 26
HEALTH MATRIX 309, 339–40 (2016) (“The War on Drugs contributes to the underuse of
buprenorphine in two ways: by stigmatizing drug-dependent individuals and by causing them to hide
their illness (rather than seeking treatment) out of fear of punishment for drug possession.”)
92
Valerie Hewell, Angel Vasquez, & Inna Rivkin, Systemic and individual factors in the
buprenorphine treatment-seeking process: a qualitative study, 12 SUBSTANCE ABUSE TREATMENT,
PREVENTION, AND POLICY 1, 4-5 (2017)
93
The Drug Addiction Treatment Act, was passed as part of the Children’s Health Act, codified at 21
U.S.C.A. § 823 (West 2019)
94
“Surprisingly, utilization of buprenorphine is very low in the U.S., partly due to restrictions placed
on prescribers under the Drug Addiction Treatment Act (DATA) of 2000. In 2013, Senator Markey
introduced the Recovery Enhancement for Addiction Treatment Act (TREAT Act) in the Senate,
which would loosen DATA's patient limit restrictions and expand prescribing ability to nurse
practitioners and physician assistants. Even though the bill was strongly supported by the American
Medical Association, American Society of Addiction Medicine, and other professional organizations,
it received scant media or public attention.” See, Barbara Andraka-Christou, America Needs the Treat
Act: Expanding Access to Effective Medication for Treating Addiction, 26 HEALTH MATRIX 309, 317
(2016)
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estimated that only half of the physicians with waivers actually prescribe
buprenorphine, and most of those prescribe far below their capacity.95
Almost half of our counties in the U.S.A. lack a buprenorphine-waivered
physician, and there is a significant gap between treatment need and
capacity. This is despite its “high potential” to treat affected individuals,
due to “its approval for use in non-specialty outpatient settings,
effectiveness at promoting abstinence, and cost effectiveness.”96 While it
can be hard to frame this concept for physicians, and may be underreported, “many physicians explicitly cite [stigma toward patients with
SUD] as a barrier.”97
It is hard to imagine another disease for which there exists such a
skimpy infrastructure for treatment. Visualize the public outcry, if nearly
half of our counties did not have a chemotherapy or dialysis clinic, and over
60% of individuals with cancer did not get evidence-based treatment. Yet
this is where we are with SUD. And it is precisely because it is seen as a
moral failing rather than as a medical disease.
II.

LEGAL RESPONSE TO STIGMA
A. Criminalization Fosters Stigma

To answer, “how did we get here?” we must look not just to the
media depictions of addicts, but to the over-criminalization of addiction.
Stigma permits criminalization, but it also is exacerbated by it. The policy
feedback literature suggests that “enactment of public policies can lead to
changes in public perceptions of the worthiness of the population targeted
by the policy and shift political power by creating new constituencies”98
Not only are policies impacted by social stigma, as politicians will rarely
expend the capital to protect heavily stigmatized groups, but therapeutic and
compassionate policies can reduce stigma. Criminalizing drug possession
does the opposite.
Recent research demonstrates that the extent to which people
stigmatize drug addiction predicts their support for punitive policies. For
example, when asked whether respondents supported arresting and
95

Lloyd I. Sederer and Leslie A. Marino, Ending the Opioid Epidemic by Changing the Culture, 89
PSYCHIATRIC QUARTERLY 891, 892 (2018)
96
Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230 (2018)
97
Rebecca Haffajee, et al., Policy Pathways to Address Provider Workforce Barriers to
Buprenorphine Treatment, 54 AM. J. PREV. MED. S230, S233 (2018)
98
McGinty, et al., 69 PSYCHIATR. SERV. 136 (2017)
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prosecuting people who “doctor shop” to obtain multiple opioid
prescriptions, roughly 17% of the variance in support for this policy could
be explained by ratings of addiction stigma.99 When researchers asked
whether respondents supported requiring Medicaid enrollees, suspected of
“problematic” opioid use to use a single prescriber and pharmacy, again
17% of the variance in support could be explained by stigma.100 Stigma
was so powerful, it shockingly explained more of the support for punitive
policies than political affiliation.101 These findings provide powerful
support for the idea that “reducing stigma toward individuals with
prescription OUD might be one way to discourage adoption of punitive
policies.”102
Of course, the criminalization of drug use has led to greater stigma
for affected individuals as well. The modern “War on Drugs” can be traced
back to President Richard Nixon, as he declared in 1971 that drug abuse
was “public enemy number one in the United States.”103 Seizing on this
perception, Congress began passing “tough on crime” laws that
criminalized use and possession of drugs, with strict mandatory minimum
sentences. This continued through the presidencies of Ronald Reagan and
George H.W. Bush.104
To build support for his “War,” the Reagan administration sought to
publicize the threat of crack cocaine. According to Michelle Alexander
“[a]lmost overnight, the media was saturated with images of black ‘crack
whores,’ ‘crack dealers,’ and ‘crack babies’—images that seemed to
confirm the worst racial stereotypes about impoverished inner-city
residents.”105 In 1986, in response to news coverage that suggested NBArecruit Len Bias had overdosed on crack cocaine, Congress adopted the
1986 Anti-Drug Abuse Act, with little debate and zero hearings.106 The Act
created a mandatory minimum sentence of five years for possessing five
99
Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid Use
Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies, 68
PSYCHIATRIC SERV. 462, 468 (2017)
100
Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid Use
Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies, 68
PSYCHIATRIC SERV. 462, 468 (2017)
101
Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid Use
Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies, 68
PSYCHIATRIC SERV. 462, 466 (2017)
102
Alene Kennedy-Hendricks, et al, Social Stigma Toward Persons With Prescription Opioid
Use Disorder: Associations With Public Support for Punitive and Public Health–Oriented Policies,
68 PSYCHIATRIC SERV. 462, 466 (2017)
103
Shima Baradaran, Drugs and Violence, 88 S. CAL. L. REV. 227, 246–47 (2015)
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Shima Baradaran, Drugs and Violence, 88 S. CAL. L. REV. 227, 249 (2015)
105
Michelle Alexander, THE NEW JIM CROW, The New Press: New York, (2012) at p. 5
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Doris Marie Provine, Race and Inequality in the War on Drugs, 7 ANN. REV. L. & SOC. SCI. 41,
45–46 (2011)
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grams of crack with intent to sell, and a minimum of ten years of
imprisonment for ten grams.107 In 1988, Congress added a five-year
minimum sentence for simple possession of 5 grams of a mixture of crack
cocaine.108 It is impossible to speak of the War on Drugs without
acknowledging how disproportionately it affected people of color. Whereas
powder cocaine, “associated with a wealthier, whiter class of drug users,”
required possession of 500 grams to trigger a 5-year prison term, one only
needed to possess a mere 5 grams of the chemically identical crack cocaine,
“regarded as a drug of the black urban ghetto,” to trigger the same
sentence.109 The disparities in sentencing were exquisitely felt by the many
black communities that were devastated by these harsh penalties. These
harsh penalties received public support, as they fell on the disempowered
and “racial other,” which in turn led to greater dehumanization of people of
color.110 The result, of course, is that in modern America, if you were to
gaze your eyes on the criminal justice system, you would think that drug
use and addiction were largely problems for the urban, poor, AfricanAmerican community. Drug addicts were the “other,” and they were
dangerous. Of course, we know now how biased this snapshot was. It did
not capture the many white and wealthy Americans who were similarly
addicted, and it did not fully capture the many people with SUD who were
neither dangerous nor involved with the criminal justice system.
The present opioid addiction crisis reveals just how racialized our
political responses can be. While it is laudable that legislators are now
proposing bills that encourage treatment and de-emphasize criminalization,
it is quite illuminating that these compassionate responses to drug addiction
have only now been proposed. Perhaps because those affected by OUD are
more likely to be white, middle-class, older, and living in the suburbs, there
has been less “othering” of people with OUD. As we might expect, the
policy and criminal justice responses to OUD do appear to be less punitive
and more therapeutic. Evidence of this can be found in the Opioid Crisis
Response Act111, a rare, bipartisan appropriation bill passed by Congress in
2018, with 99 Senators supporting the bill. The Act provides modest
funding for research into addiction stigma, and increases housing options
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Doris Marie Provine, Race and Inequality in the War on Drugs, 7 ANN. REV. L. & SOC. SCI. 41,
45–46 (2011)
108
Doris Marie Provine, Race and Inequality in the War on Drugs, 7 ANN. REV. L. & SOC. SCI. 41,
45–46 (2011)
109
Doris Marie Provine, Race and Inequality in the War on Drugs, 7 ANN. REV. L. & SOC. SCI. 41, 46
(2011)
110
Doris Marie Provine, Race and Inequality in the War on Drugs, 7 ANN. REV. L. & SOC. SCI. 41, 42
(2011)
111
SENATE BILL 2680 - Opioid Crisis Response Act of 2018, AVAILABLE ONLINE AT
https://www.congress.gov/bill/115th-congress/senate-bill/2680/text
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for people in recovery.112 Additionally, several federal agencies have
responded to the opioid crisis with a much more therapeutic and preventionbased approach.113 However, there remains a dire need for more funding of
addiction treatment programs and scaling-up of physicians authorized to
provide MAT.114
The Department of Health and Human Services (“HHS”) developed
a five-point evidence-based strategy in 2017. The five points are: (1)
increasing addicts’ access to recovery and treatment services; (2) improving
access to medications that reverse overdoses; (3) improving data collection;
releasing data more promptly to improve public health response; (4)
research into pain and addiction, including development of new treatments;
(5) reducing inappropriate use of opioids by developing better evidencebased pain treatment.115 This effort is laudable, and does exactly what
should be done: treating addiction as a disease with devastating public
health impacts. We certainly saw no such political response to the Crack
Cocaine epidemic of the 1980s and 1990s, which dehumanized addicts and
criminalized addiction.
Despite the greater efforts to respond to OUD through drug courts116
and harm reduction programs117, addiction remains heavily criminalized.
112

Sec. 404 of the Opioid Crisis Response Act states, “Building communities of recovery: This
section awards grants to recovery community organizations, five million dollars each fiscal year from
2019-2023. Recovery community organizations are independent non-profit organizations that
mobilize resources and are governed by people in recovery for substance abuse disorders. The funds
may be used to build connections between recovery networks and other recovery support services,
reduce the stigma associated with substance use disorders, and conduct outreach on issues relating to
substance use disorders and recovery. The Secretary shall give special consideration in awarding
these grants to rural areas.”
113
Given the high rates of opioid addiction in the Medicare population, the Centers for Medicare and
Medicaid Services (“CMS”) now require much more oversight when Medicare beneficiaries are
prescribed opioids. All Medicare Part D plan sponsors are “required to have a written plan to reduce
overuse of opioids, using tools such as case management, coordinated care among beneficiaries’
doctors, better management of the plan’s formulary, and safety edits when patients fill prescriptions.”
See, Dana Schilling, Senior Citizens and the Opioid Crisis, 328 ELDER LAW ADVISORY NL 1 (2018)
Additionally, recognizing the systemic factors that can drive addiction, the Food and Drug
Administration (FDA) now requires prescriber education for opioids. Nearly half of the states have
received Center for Disease Control (“CDC”) grants to “prevent, deal with, and track overdoses,” and
44 states obtained CDC grants to fund prescription drug monitoring programs (PDMPs). See, id.
114
Lancet Editorial: The Opioid Crisis in the U.S.A.: a public health emergency, 390 LANCET
2016, 2016 (2017)
115
Testimony of Giroir and Brandt, Senate Committee on Finance Hearing: Tackling Opioid and
Substance Use Disorders in Medicare, Medicaid, and Human Services Programs, available at
https://www.finance.senate.gov/download/04192018-joint-testimony, at p. 3, see also, Dana
Schilling, Senior Citizens and the Opioid Crisis, 328 ELDER LAW ADVISORY NL 1 (2018).
116
Barbara Andraka-Christou, What Is "Treatment" for Opioid Addiction in Problem-Solving Courts?
A Study of 20 Indiana Drug and Veterans Courts, 13 STAN. J. CIV. RTS. & CIV. LIBERTIES 189, 191
(2017) (“Unlike regular courts whose primary duty it is to arbitrate civil and criminal issues,
problem-solving courts focus on solving underlying problems of communities through the
rehabilitation of offenders in the criminal justice system.2 Drug courts are one type of problemsolving court…”)
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According to the Federal Bureau of Investigation statistics, in 2016 alone,
1.57 million drug arrests were made in the United States.118 That is one drug
arrest every 20 seconds, and represents more than three times the arrests
made for all violent crimes combined.119 In 2015, the overwhelming
majority of drug arrests, some 84%, were for possession only, and did not
include distribution or sales of drugs.120
The stigma from incarceration itself can lead to a “why try?” effect,
where people anticipate stigma and thus see no point in trying to integrate
back into their communities.121 Conviction can also reduce access to other,
derivative rights. Having a criminal record tied to drug use can negatively
impact child custody, voting rights, employment, business loans, licensing,
student aid, and even public housing.122 While it is not unfair discrimination
to deny someone custody of their child when they are too dependent on
opioids to safely take care for their kids, the concern here is that the label of
“addict” will be doing too much punitive work. Rather than evaluating the
antisocial behavior of that individual, the label of “addict” will alone
persuade judges to deny parents custody in ways that might not be in the
child’s best interests.
To be sure, criminalization of addiction would be better justified,
even given the stigma it creates, if it worked to deter drug use. But based on
data compiled by the Pew Charitable Trust, imprisonment for drug crimes
does not reduce drug use, arrests, or overdose deaths.123 By any measure
that matters, criminalization is not working.124 In 2000, Portugal
decriminalized drug use and replaced criminal sanctions for those who
possessed more than a small amount with civil penalties and public health
117
Danielle Atkins, et al., Good Samaritan Harm Reduction Policy and Drug Overdose Deaths,
Health Serv. Research, epub ahead of print, doi: 10.1111/1475-6773.13119. (2019); David Cloud, et
al., Syringe Decriminalization Advocacy in Red States: Lessons from the North Carolina Harm
Reduction Coalition, 15 CURRENT HIV/AIDS REPORTS 276. 276 (2018)
118
Federal Bureau of Investigation, 2016 Crime in the United States, available online at
https://ucr.fbi.gov/crime-in-the-u.s/2016/crime-in-the-u.s.-2016/cius-2016
119
Drug Policy Alliance, New FBI Report Shows Drug Arrests Increased in 2016, As Drug War
Rages On, Sept. 25, 2017, available online at http://www.drugpolicy.org/press-release/2017/09/newfbi-report-shows-drug-arrests-increased-2016-drug-war-rages
120
Drug Policy Alliance, New FBI Report Shows Drug Arrests Increased in 2016, As Drug War
Rages On, Sept. 25, 2017, available online at http://www.drugpolicy.org/press-release/2017/09/newfbi-report-shows-drug-arrests-increased-2016-drug-war-rages
121
Kelly Moore, et al, The Effect of Stigma on Criminal Offenders’ Functioning: a longitudinal
mediation model, 37 DEVIANT BEHAV. 196, *17 (2016)
122
Sources: U.S. Census Bureau; Bureau of Justice Statistics; and
http://www.drugpolicy.org/resource/drug-war-mass-incarceration-and-race-englishspanish
123
PEW Issue Brief, More Imprisonment Does Not Reduce State Drug Problems: data show no
relationship between prison terms and drug misuse, March 8, 2018, available online at
https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2018/03/more-imprisonment-doesnot-reduce-state-drug-problems
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Brendan Saloner, et al., A Public Health Strategy for the Opioid Crisis, 133 PUBLIC HEALTH
REPORTS 24S, 26S (2018)
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interventions.125 Dr. João Goulão, Portugal’s national drug policy director
who led the reform said, “the biggest effect has been to allow the stigma of
drug addiction to fall, to let people speak clearly and to pursue professional
help without fear.”126 The country has seen a steady decline in the rate of
new HIV infections as well as overdose deaths.127
B. Anti-Discrimination Statutes Cannot Effectively Mitigate
Stigma
Anti-discrimination statutes prohibit discrimination based on
someone’s identity or observable characteristics. We therefore have federal
statutes that prohibit discrimination in housing, employment, and public
accommodations, based upon specific protected statuses, such as race,
religion, sex, disability status, or genetic mutations. Another way of
thinking about this is to require that people judge someone based on the
content of their actions rather than on their belonging to a particular group,
which is typically stigmatized. To demonstrate how the anti-discrimination
statutes work in the context of addiction, let’s analyze the Americans with
Disabilities Act (“ADA”).
Recognizing that people with physical or mental disabilities have
rights to fully participate in all aspects of society, Congress passed the ADA
to prohibit discrimination in employment and public accommodation128. It
was later amended in 2008. The ADA prohibits companies with more than
fifteen employees from discriminating against a qualified individual on the
basis of that person's disability, or perceived disability.129 Addiction
qualifies as a disability, if it physically or mentally impairs the employee
and limits the employee in a major life activity, such as learning or taking
care of oneself.130 Once an employer is aware of an ADA-defined disability,
she must then make “reasonable accommodations to the known physical or
mental limitations” of the individual.

125

Hannah Laqueur, Uses and Abuses of Drug Decriminalization in Portugal, 40 LAW & SOC.
INQUIRY 746, 747 (2015) (“The law did not alter the criminal penalty prohibiting the production,
distribution, and sale of drugs, nor did it permit and regulate use. Rather, Portugal decriminalized
drug use, which, as defined by the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), entailed the removal of all criminal penalties' from acts relating to drug demand: acts of
acquisition, possession, and consumption.”)
126
NIGEL HAWKES, HIGHS AND LOWS OF DRUG DECRIMINALISATION, 343 British Medical Journal 1, 1
(2011)
127
European Monitoring Centre for Drugs and Drug Addiction, “European Drug Report: Trends and
Development” (Luxembourg, 2015).
128
AMERICANS WITH DISABILITIES ACT OF 1990, PL 101–336, July 26, 1990, 104 Stat 327,
later revised PL 110-325 Section 3 (Sept. 25, 2008).
129
See 42 U.S.C.A. § 12102 (West 2019)
130
See, 42 U.S.C.A. § 12102 (West 2019)

Electronic copy available at: https://ssrn.com/abstract=3345176

1-Mar-19]

Addiction as Disease

24

There are a few ways that the anti-discrimination statutes, such as
the ADA, will not be enough to protect people with SUD from illegal
discrimination. In theory, addiction can meet the definition of a disability,
and therefore must be accommodated so long as the accommodation does
not create an “undue burden” for the employer.131 But in practice, it is easy
to fire people with SUD, or exclude them from broad classes of
employment. First, if you are ever intoxicated at work, your behavior is
understandably grounds for discipline and is not protected by the ADA.132
Even so, the employer must apply any disciplinary policies equally to all
affected employees.133 If your intoxicated behavior embarrassed the
company, even it occurs outside of your employment, you may be fired and
it will not violate the ADA.134 There are often pretextual reasons to
terminate someone with an addiction. If you are covering your addiction
well, you will not be protected under the ADA, as the employer needs to
regard you as having a disability.135 It is often difficult to prove that the
employer knew of your addiction unless you exhibit intoxicated behavior, in
which case you are also not protected. If you are recently using, you are not
a qualified person with a disability, and are not protected under the ADA or
the Family Medical Leave Act, even if none of your behavior led your
employer to believe you were impaired.136. If you disclose your SUD to
seek unpaid time off for treatment, employers can then fire you and claim it
is due to a business necessity reason, even if they had no idea you had any
problem before you alerted them. If someone is participating in an addiction
treatment program, has successfully completed a treatment program, or is
no longer using illegal drugs, they are not excluded as a “qualified
individual.”137 However, once an employer knows about an employee’s
SUD, the “business necessity” exception provides for far-reaching
exclusions to protection, even for people who are now sober.138 Further, if
you are now sober, some courts will hold that you are no longer
131
For example, employees must allow for a leave of absence so employees can seek treatment for
substance use disorder, if the treatment is “likely to be successful” and it does not create an “undue
hardship” on the employer. See, Schmidt v. Safeway, 864 F. F. Supp. 991 (D. Ore. 1994)
132
Renaud v. Wyoming Department of Family Services, 203 F.3d 723 (2000); see also
133
Flynn v. Raytheon Co., 868 F. Supp. 383 (D. Mass. 1994)
134
See Maddox v. University of Tennessee, 62 F.3d 843 (6th Cir. 1995); see also Labrucherie v.
Regents of the Univ. of California, U.S. app. LEXIS 17755 (9th Cir. 1997)
135
Larson v. Koch Ref. Co., 920 F. Supp. 1000 (D. Minn. 1995)
136
See Zenor v. El Paso Healthcare System, 176 F.3d 847 (5th Cir. 1999) See also, 42 U.S.C.A §
12114 (West 2019)( “For purposes of this subchapter, a qualified individual with a disability shall not
include any employee or applicant who is currently engaging in the illegal use of drugs, when the
covered entity acts on the basis of such use.”)
137
42 U.S.C.A. § 12114 (West, 2019)
138
42 U.S.C.A. § 12113 (West, 2019); See also, EEOC v. Exxon Corp. 967 F. Supp. 208 (N.D. Tex
1997) (Exxon successfully argued that, due to the high rates of relapse among rehabilitated substance
abusers, they could exclude all of them from “designated positions,” even without performing an
“individualized assessment.”)
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experiencing a “disability,” nor are you “regarded as having a disability,” if
the impairment to your life is not substantial enough.139 This of course
confuses the status of someone in recovery, as “in this context, [sobriety] is
not synonymous with a cure; it is a personal process of movement toward a
meaningful, purposeful, and satisfying life.”140 Despite the stigma attached
to current or previous SUD, employees are not fully protected from
discrimination while they are keeping their behavior under control, while
they are using, while they are exhibiting behavior of intoxication, or when
they are in recovery. This leaves very little protection for people with SUD.
Given the problems with addiction being a heavily stigmatized disorder
based on biology and behavior, it does not fit neatly within the classes
protected under various anti-discrimination statutes. As illustrated in its
ineffective protection under the ADA, it is no wonder that people with SUD
are regularly discriminated against.
In addition to stigma toward SUD, its treatment is stigmatized too.
The Legal Action Center in New York reports that nursing homes are
discriminating against potential elderly residents who use MAT (such as
methadone or buprenorphine), and will deny them residency based upon
their MAT use. Some organ transplant patients cannot be listed if taking
MAT,141 and in other instances MAT patients have been forced to taper to
maintain custody or their jobs. This sort of discrimination for receiving
medical treatment, is not protected by the ADA or other federal antidiscrimination statutes. State anti-discrimination statutes might provide
greater, but still spotty, protection.
III.

THE MORAL CHOICE MODEL MUST BE REPLACED WITH THE IDM
A. The Competing Causal Models of Addiction

A well-accepted view of SUD is that it unfolds as a three-step
process. First comes the binge or intoxication episodes. After enough of
these episodes, some individuals will become addicted (either through weak
character, as some posit, or through genetic vulnerability to physical
dependence, as I suggest). Once the drug is metabolized there is a hangover, which leads to negative affect and withdrawal symptoms. This in turn
leads to the third step of preoccupation, where desire for the drug intensifies
139

Johnson v. NYC Office of Alcohol, LEXIS 41986 (S.D. N.Y. 2018)
National Academies of Science, Ending Discrimination Against People with Mental and
Substance Use Disorders: The Evidence for Stigma Change, available for download at
http://nap.edu/23442, at p. 1
140
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Woods & Joseph, Stigma from the Viewpoint of the Patient.
34 J. Addictive Dis 247 (2015)

Electronic copy available at: https://ssrn.com/abstract=3345176

1-Mar-19]

Addiction as Disease

26

and prompts the next intoxication episode.142 This three-step process
describes the cycle of drug use, whether you think of this process in terms
of a learning, memory, developmental, reward, impulse, or chemical or
neuroinflammatory disorder. Stressful life events can lead to continued drug
use to self-medicate and escape the stress or pain.143
How we conceive of addiction impacts our response.144 Some have
argued that “whether addiction is a disease is much ado about nothing, since
all parties agree it is ‘unquestionably destructive.’”145 But it does matter.
While our current moral agency model discourages investments in treatment
and encourages investment in criminalization, a model that is on equal
footing with lung cancer or diabetes permits greater research funding and
insurance parity. So how do we get there? We first need to dig a little
deeper into the various models.
There are as many models of addiction as there are drugs to abuse. It
makes sense then, that our policy response to addiction has been
inconsistent and fractured. Scholars have argued that the best way of
conceptualizing addiction is to see it as either a disorder of development,
trauma, risk-taking, choice, associative reward learning, memory, opponent
biological processes, genetics, or neuroscience. Unfortunately, many see
these as dichotomous and competing, as opposed to complementary.146
Most scholars keen on identifying the “correct” model of addiction fall in
the mutually exclusive “brain disease” or “moral choice” camps, even
though there are many other models.147 Philosophers and legal scholars
have spilled much ink on this “oftentimes heated scholarly debate” as to
whether we ought to think of addiction as a moral choice or a disease.148
142
Emmanuel Darcq and Brigitte Lina Kieffer, Opioid Receptors as “Drivers” of the Onset,
Progression, and Maintenance of Addiction, 19 NATURE REVIEWS NEUROSCi 499, 504 (2018)
143
Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *1 (2016)
144
“[H]ow patients understand their addiction may shape their health behaviors, relationship with
their care team, and willingness to accept treatment.” See Helen Jack, et al., THE AMERICAN J. OF
MEDICINE e1, e1 (2018)
145
OWEN FLANAGAN, ADDICTION DOESN’T EXIST, BUT IT IS BAD FOR YOU, 10 NEUROETHICS 91, 91 (2017)
146

As every single one of these processes is mediated by the brain and any deficits can be explained
in terms of brain circuitry and chemistry, they are easily adopted into an explanatory model that
emphasizes brain disorder. The moral choice model stands alone in terms of failing to make any
explanatory space for addiction as a disorder of neurological and psychological processes. Marc
Lewis, Addiction and the Brain: development, not disease 10 Neuroethics 7, 8 (2017)
147
“Long-standing debates concerning the moral status of addiction have arisen from one of two
perspectives: either addiction is a disease of the brain, or addiction is a matter of weak will.” See,
Daniel Buchman, Wayne Skinner, and Judy Illes, Negotiating the Relationship Between Addiction,
Ethics, and Brain Science, 1 AJOB NEUROSCIENCE 36, 40 (2010)
148
Lily Frank and Saskia Nagel, Addiction and Moralization: the role of the underlying model of
addiction, 10 NEUROETHICS 129, 129 (2017) (He writes, that “[w]hat most don’t see because of the
meager dialectical offerings – addiction is either a moral or a brain/gene disorder – is the prospect
that one can see addiction as involving biographically interpretative assessment of one’s own reason

Electronic copy available at: https://ssrn.com/abstract=3345176

1-Mar-19]

Addiction as Disease

27

Though most neuroscientists, leading addiction researchers, and
even government entities promote addiction as a chronic brain disease149, a
recent review shows “varied adoption of the brain disease model among
addiction treatment providers, with some viewing addiction as a purely
behavioral problem or maladaptive coping mechanism.”150 The disease
model is typically associated with being less moralized, as the emphasis is
not on the moral character of the individual, but rather on biological risk
factors, and a brain that becomes compelled to use drugs.151 The choice
model invites greater ascriptions of stigma, blame and personal
responsibility for choosing hedonism over abstinence.152 The moral choice
model is the one we see most often in our history and popular culture. It has
done great violence to the treatment of addiction, both individually and as a
public health crisis.
B. The Moral Choice Model of Addiction
Those advocating the “choice model” emphasize that people can
and do stop using drugs, with sufficient incentives.153 Some (though not
many) people with SUD achieve recovery without any medical treatment,
and they may have never identified with being “sick” or now “cured.”154 To
this camp, addiction is a failure to exercise agency or self-control, as well as
a failure to “live up to the standards of a good life.”155 Some of the moral
choice theorists posit that personal shame is a necessary condition for
addiction, but that shame need not result in a “moralized” view of
addiction.156 This interpretation strains credulity. The examples they
provide, of people feeling ashamed of things that are outside their control,
such as body deformities, are likely holdovers from shame that was directed
at people thought to carry infection. To continue this sort of blameless
shame, or suggest that addiction relies upon it, is to continue this sort of
irrational holdover.
responsiveness failings as well as moral failings without either the addict herself or her community
moralizing and blaming her.”)
149
Marc Lewis, Addiction and the Brain: development, not disease, 10 Neuroethics 7, 7 (2017)
150
See Helen Jack, et al., THE AMERICAN J. OF MEDICINE e1, e1 (2018)
151
“[T]he disease-model ha[s] held that addictive behavior is a compulsion – beyond one’s conscious
control and without regard for one’s rational judgment – to indulge in particular behaviors or in the
consumption of certain drugs.” See, Lily Frank and Saskia Nagel, Addiction and Moralization: the
role of the underlying model of addiction, 10 NEUROETHICS 129, 130 (2017)
152
Lily Frank and Saskia Nagel, Addiction and Moralization: the role of the underlying model of
addiction, 10 NEUROETHICS 129, 136 (2017)
153
Stephen Morse, Addiction, genetics, and criminal responsibility, 69 LAW AND CONTEMPORARY
PROBLEMS 165, 169 (2006) Of course, the percentage who recover without treatment is quite low. See
infra, [discussion of MAT].
154
Marc Lewis, Addiction and the Brain: development, not disease 10 Neuroethics 7, 8 (2017)
155
Owen Flanagan, Addiction Doesn’t Exist, But it is Bad for You, 10 NEUROETHICS 91, 91 (2017)
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Steve Matthews, et al., Stigma and Self-Stigma in Addiction, 14 BIOETHICAL INQUIRY 275, 279
(2017);
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Proponents of the choice model argue that aspects of drug-taking
require voluntary action, such as driving to meet a dealer, or leaving work
early to shoot-up.157 Further, the pleasure that may be derived from
satisfying a drug craving is understood by some as a rational expression of
individual preference.158 And rather than seeing the brain changes that can
be visualized in people with SUD as evidence of a brain disease, they argue
that the very nature of the brain is to change. Thus, brain changes are not
equivalent to disease.159
While the choice model is the one that most readily lends itself to an
account that blames the addict and finds them morally responsible, there are
aspects of the choice model that proponents argue may benefit individuals
with SUD. For example, envisioning addiction as a brain disease might take
too much pressure off society to prevent its social determinants, such as
housing, unstable home lives, personal safety, and employment.160 Further,
deterministic thinking might lead people with SUD to give-up efforts at
sobriety if the disease is “fixed” in their brains. Of course, this characterizes
just one way that the disease model can be operationalized, and assumes
that there is insufficient funding to address treatment and the public health
aspects of addiction.161
C. The Brain Disease Model of Addiction
In contrast to the choice model, the disease model of addiction
conceptualizes it as a “severe, chronic stage of substance-abuse disorder, in
which there is substantial loss of self-control, as indicated by compulsive
drug-taking despite the desire to stop taking the drug.”162 The definition
from the National Institute on Drug Abuse (NIDA) goes further to state that
157
Neil Levy, Addiction and self-control: perspectives from philosophy, psychology and
neuroscience, Oxford: Oxford University Press (2013)
158
Lily Frank and Saskia Nagel, Addiction and Moralization: the role of the underlying model of
addiction, 10 NEUROETHICS 129, 130 (2017)
159
Lily Frank and Saskia Nagel, Addiction and Moralization: the role of the underlying model of
addiction, 10 NEUROETHICS 129, 130 (2017)
160
Wayne Hall, et al., Brain Disease Model of Addiction: misplaced priorities, 2 LANCET
PSYCHIATRY 867, 867 (2015); Neil Levy, Addiction Is Not a Brain Disease, (and It Matters), 4
FRONTIERS IN PSYCHIATRY 24, *6 (2013); Anthony Barnett, et al., Drug and Alcohol Treatment
Providers’ Views About the Disease Model of Addiction and Its Impact on Clinical Practice: a
systematic review, 37 DRUG AND ALCOHOL REVIEW 697, 697 (2018)
161
While the federal Opioid Crisis Response Act of 2018 allocated funds to research and treatment,
some argue it did not go far enough. See, German Lopez, Congress is on the verge of a bipartisan
opioid package. But experts have big concerns, Vox, Sept. 12, 2018, available online at
https://www.vox.com/policy-and-politics/2018/9/12/17847358/senate-opioid-crisis-response-act.
Additional sources of funding are being made available by the Centers for Disease Control, National
Institutes of Health, and state agencies. See, N.J. Stat. Ann. § 24:6J-6 (West); see also Cal. Health &
Safety Code § 1179.80 (West); See also Lexy Gross, The Opioid Epidemic and Rural America: Why
the USDA Should Lead the Response, 10 KY. J. EQUINE, AGRIC. & NAT. RESOURCES L. 257, 277
(2018)
162
Nora Volkow, et al., Neurobiological advances from the brain disease model of addiction, 374 N.
ENG. J. MED. 363, 364 (2016)
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addiction “is considered a brain disease because drugs change the brain—
they change its structure and how it works. These brain changes can be
long-lasting, and can lead to the harmful behaviors seen in people who use
drugs.”163 While addiction no doubt changes the brain, the IDM I advocate
goes further than merely demonstrating brain changes through functional or
structural brain imaging. Rather, the IDM recognizes that neurobiological
vulnerabilities can lead to addiction, as opposed to just flow from it. It
further situates the brain inside a human being, which has been exposed to
various environmental stressors and responds differently to drug use. Given
the potential nuance that a disease model such as the IDM provides, it is
perplexing that scholars fail to see how it can accommodate and respond to
its critics.
Nonetheless, the brain disease model of addiction remains
controversial.164 I have given a great deal of thought as to why this might be
so. I believe proponents of the brain disease model have unnecessarily overplayed their hand, and painted addiction in neuro-essentialist and
deterministic ways.165 Using metaphors like the “hijacking” of the brain,
some suggest that the compulsion to use drugs is so great that you might not
be legally responsible for criminal acts stemming from your addictive
behaviors. But the latter does not flow from the former, because the brain is
never completely hijacked.
Put simply, some advocates for the brain disease model have fallen
into the same trap the moral choice camp has fallen in to, which is to think
that free will and biological causes are mutually exclusive. Addiction is
either a disease of the brain or it is a voluntary, moral choice. One or the
other. Black and white. However, to say that addiction is a brain disease is
not to say that the affected individual loses all capacity to make reasonsbased decisions. Even Owen Flanagan, who argues that addiction is a
failure of agency, recognizes that the dichotomy between morality and
biology is false.166 There are aspects of addiction that suggest the person is
making some constrained choice, and there are aspects of addiction that
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National Institute on Drug Abuse, National Institutes of Health, Drugs, Brains and Behavior: the
science of addiction, available online at www.drugabuse.gov/publications/drugs-brains-behaviorscience-addiction/drug-abuse-addiction, at p. 2.
164
Nora Volkow and George Koob, Brain Disease Model of Addiction, why is it so controversial? 2
LANCET PSYCHIATRY 677, 677 (2015)
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Daniel Buchman, Wayne Skinner, and Judy Illes, Negotiating the Relationship Between
Addiction, Ethics, and Brain Science, 1 AJOB Neuroscience 36, 36 (2010) (“Although a brain
disease model legitimizes addiction as a medical condition, it promotes neuro-essentialist thinking,
categorical ideas of responsibility and free choice, and undermines the complexity involved in its
emergence.”)
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Owen Flanagan, The Shame of Addiction, 4 FRONTIERS IN PSYCHIATRY 120 (2013)
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follow a brain disease model.167 “Endorsing a [disease model of addiction]”
is not “inconsistent” with a free-will model.168
Conversely, even if there is a voluntary choice involved in the
decision to use drugs for the first, second, or third times, once someone has
developed SUD, all of their “choices,” including those unrelated to drug
use, do become significantly constrained, if not perfectly determined.169 The
volitional nature of behavior is more pronounced in the initiation phase of
disease, but brain adaptations can reduce volition leading to habits, altered
reward processing, stress reactivity, and negative affect and physiology of
withdrawal.170 More will be said about this infra at [x].
D. Neither Purely a Brain Disease nor Purely a Moral Choice:
the IDM
In adopting the IDM, we need not rely on the “fundamental psycholegal error.” The disease model does not suggest that addiction is caused
only, or even predominantly, by the brain. What’s more, this Article is
about moral justifications for treatment, not moral justifications for
punishment. While our models of addiction impact our criminal laws, it is
not an inevitable step from a disease model to an argument that would
necessarily be relevant to the criminal law.171 Neuro-genetic factors are but
one of many relevant types of causes. A disease model would hopefully
encourage compassion in how we prosecute drug possession, just as a
history of child abuse or other psychiatric disorders might engender mercy.
But that does not mean that the individual could never be legally
responsible for his actions. Indeed, with increased access to effective and
167

Rather than being a disease or a choice, addiction might be the result of psychological or
neurological mechanisms that diminish reasons-responsiveness, due to associative learning. For
example, according to Marc Lewis, addiction is a “habit that grows and self-perpetuates relatively
quickly, when we repeatedly pursue the same highly attractive goal. Or, in a phrase, motivated
repetition that gives rise to deep learning.” Marc Lewis, THE BIOLOGY OF DESIRE: WHY ADDICTION IS
NOT A DISEASE, New York: Public Affairs, at p. 174 (2015)
168
Anthony Barnett, et al., Drug and Alcohol Treatment Providers’ Views About the Disease Model
of Addiction and Its Impact on Clinical Practice: a systematic review, 37 DRUG AND ALCOHOL
REVIEW 697, 717 (2018)
169
“Observers will continue to rate the addict as culpable long after the drug is ingested for ‘personal
choice’ and functional dysregulation and structural alterations have materialized in brain areas that
regulate motivation and self-regulation in the face of escalating consequences.” G.F., Koob, and M.
Le Moal. What is addiction, NEUROBIOLOGY OF ADDICTION. Koob and Le Moal (eds),
Elsevier/Academic Press, Amsterdam/Boston (2006): 1-22.
170
Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *7 (2016)
171
“[D]iscovery of genetic or of any other physical or psychosocial cause of action raises no new
issues concerning responsibility, and discovery of such causes does not per se create an excusing or
mitigating condition for criminal conduct or any other type of behavior.” Stephen J. Morse,
Addiction, Genetics, and Criminal Responsibility, LAW & CONTEMP. PROBS., Winter/Spring 2006, at
165, 166.
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cheaper SUD treatments in the future, prosecutors might have greater moral
justification for prosecuting people who do not seek it.
Finally, adopting the IDM does not require that the individual with
SUD be capable of being “cured.” There are many diseases for which a cure
is never likely, and the best that can be hoped for is remission or sustained
recovery.172 And treating addiction as a disease does not mean that we
should ignore the social determinants of health, such as high-stress
environments,173 just as we should not ignore the social determinants of
lung cancer, diabetes, depression or AIDS. Many of the criticisms of the
brain disease model rely on misunderstandings of the complex etiology of
‘disease,’ and bring to bear a very constrained model of what it means for
something to be a choice, as well as what it means for something to be a
disease. The two are not wholly incompatible. What can be said,
uncontroversially, is that whether one adopts a disease model, a choice
model, or something else, that the mechanisms involved in addiction are
neurobiological. The three phases of addiction are craving, binging, and
withdrawal, and the resulting physical dependence can be understood and
explained by neurobiological mechanisms. Further, the process from drug
use to mild SUD, to moderate SUD, and then to severe SUD, otherwise
labeled full-blown addiction, can be explained by neurobiological
systems.174
E. The Neurobiology of Addiction Does Not Support the Moral
Choice Model
1. The Brain is Not Hijacked, but Is Constrained in Patients with SUD
The neurological processes behind the development of addiction
have been extensively studied. There are different ways to explain what is
happening at both the neurological and psychological levels. I will offer a
few of those explanations here, all of which fit neatly within the IDM. It is
well accepted that drugs activate reward regions in the brain by causing
sharp increases in the release of dopamine, which sets off a cascade of
172

Examples include lung cancer, anorexia nervosa, and substance use disorder.
Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *6 (2016)
174
Substance use disorder (SUD) is a diagnostic term used in the DSM-5 referring to recurrent use of
alcohol or other drugs that cause clinically and functionally significant impairment. This disorder can
be classified as mild, moderate, or severe. Addiction is used to indicate the most severe stage of this
SUD process, in which individuals have a substantial loss of self-control, and will use the drug
despite the desire to stop, and in the face of negative consequences. See, Nora Volkow, et al.,
Neurobiologic Advances From the Brain Disease Model of Addiction, 374 NEW ENG. J. MED. 363,
364 (2016).
173
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reinforcement learning and Pavlovian conditioning.175 As with any other
form of motivated learning, the greater the associated reward, the more
work someone is willing to do to get it.176 When it comes to “natural
reward,” dopamine cells reduce their firing in response to food or sex, once
someone is considered sated. This is not the case with drugs, which can
circumvent the satiation mechanisms of the brain.177 However, this effect
tapers off. With repeated use, dopamine cells cease firing in response to the
drug itself, and instead fire in anticipation of the conditioned stimuli, or
drug cue.178
Another complementary way of explaining drug use is in terms of
“opponent process” theory. Under this explanatory model, once the positive
euphoric state is triggered (the a-process), brain mechanisms will work to
reduce the intensity of this affective state (the b-process). The intoxication
phase, or the “a-process,” motivates the individual to seek more of that
pleasurable stimuli—in this case drugs.179 The a-process does this by
triggering dopamine and opiate peptides to bind to receptors in the VTA
and nucleus accumbens, which mirrors the reinforcement learning
process.180
After the effects of an opioid wear off, the b-process begins. This bprocess produces sharp declines in dopamine and opioid peptide neurons,
and increases stress steroids such as adrenaline and corticotropin-releasing
factor (CRF). While these operate to return an individual to baseline, in
someone with SUD, the b-process fuels the addiction, by generating
physical dependence and withdrawal at the synaptic level. The sharp
increase in CRF and adrenaline, coupled with the desensitization of
dopaminergic receptors and the release of dynorphin, leads to mood
irritability, emotional pain, malaise, dysphoria, alexithymia, and as
discussed above, increases the threshold for experiencing reward.181 The
pathway between the paraventricular nucleus of the thalamus (PVT) and the
nucleus accumbens has been identified as a prominent neural circuit in
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Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374
NEW ENG. J. MED. 363, 364 (2016).
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Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374
NEW ENG. J. MED. 363, 366 (2016).
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Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374
NEW ENG. J. MED. 363, 366 (2016).
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Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374
NEW ENG. J. MED. 363, 364 (2016).
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George Koob and Michel Le Moal, Neurobiological mechanisms for opponent motivational
processes in addiction, 363 PHIL. TRANSACT. OF THE ROYAL SOCIETY 3113, 3114 (2008).
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George Koob and Michel Le Moal, Neurobiological mechanisms for opponent motivational
processes in addiction, 363 PHIL. TRANSACT. OF THE ROYAL SOCIETY 3113, 3120 (2008).
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George Koob and Michel Le Moal, Neurobiological mechanisms for opponent motivational
processes in addiction, 363 PHIL. TRANSACT. OF THE ROYAL SOCIETY 3113, 3120 (2008).
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relaying aversion and memory of withdrawal symptoms.182 Amazing new
research, silencing this pathway through optogenetics, suppressed
physiological withdrawal and aversion in the drug dependent state.183 This
sort of methodology, that can demonstrate cause and effect by disrupting
the neural circuitry of the “addicted brain,” is promising, but in need of
replication.
Repeated exposure to dopamine-triggering drugs leads to adaptions
in the circuitry of the brain, most notably in the striatum, ventral tegmental
area, (VTA) and basal forebrain.184 Eventually the intensity of this aprocess euphoria levels off in response. We can see this as each time the
same drug is used, the release of dopamine is diminished in the synapses.185
This explains why people with addiction “chase the dragon,” and no longer
experience the same euphoria they first experienced when using the drug.
This eventual attenuation makes the brain’s reward system much less
sensitive to stimulation of rewards of all types—including drugs but also
food, relationships, and activities.186 The neuroscientific changes are
engrained in the brain and take a long time to reverse.187 It is because of
this altered neurobiology that the analogy of addiction to lung cancer or
diabetes stops being helpful, however. Addiction is different. The disease
itself can lead you to sabotage your own recovery, by creating a
physiological pull to use drugs, despite strong personal desires to quit. It
would be as if lung addiction had a symptom that made you averse to
chemotherapy or surgery. Once someone develops the disorder of addiction,
the motivation to use drugs can eclipse the motivation to eat or sleep.
Avoiding withdrawal might become the chief motivating factor in one’s
life.
The brains of people with severe SUD have adapted to expectations
of sustained, high volume drug use, and at the same time their receptors are
increasingly insensitive to the dopamine that is being produced. This helps
182

Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *7 (2016)
183
Christopher Evans and Catherine Cahill, Neurobiology of Opioid Dependence in Creating
Addiction Vulnerability, 5 F1000 RESEARCH 1748, *7 (2016)
184
JOSHUA JENNINGS, ET AL., DISTINCT EXTENDED AMYGDALA CIRCUITS FOR DIVERGENT MOTIVATIONAL
STATES, 496 Nature 224, 224 (2013)
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“[D]rug consumption triggers much smaller increases in dopamine levels in the presence of
addiction (in both animals and humans) than in its absence (i.e., persons who have never used drugs.”
See, Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374
NEW ENG. J. MED. 363, 366 (2016).
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“[D]rug consumption triggers much smaller increases in dopamine levels in the presence of
addiction (in both animals and humans) than in its absence (i.e., persons who have never used drugs.”
See, Nora Volkow, et al., Neurobiologic Advances From the Brain Disease Model of Addiction, 374
NEW ENG. J. MED. 363, 366 (2016).
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to explain the observed behavior of people with addiction. Neural circuit
adaptations make individuals more reactive to stress.188 This in turn leads to
greater vulnerability to depression and anxiety, which in turn can lead to
greater drug use as a form of “self-medication” to ease the anxiety.189 Many
say that they really want to stop using, but get caught in the vicious cycle of
administering drugs to escape the anxiety and physical distress that is
produced by their vulnerable neuro-circuitry, and physical withdrawal. And
at the same time, what used to be an impulsive, or voluntary, choice to use
drugs has now become much more compelled.
Trevor Robbins’ lab at Cambridge has studied this shift in
neurobiology when people go from impulsive to compulsive drug use.190 He
posits that individuals first associate the drug with either euphoria or just
relief from aversive conditions.191 Then, when drug use is escalated, in
vulnerable individuals it leads to dependence. More will be said about what
makes individuals vulnerable, infra, at [x]. The third step to addiction, or
severe SUD, comes when reward circuitry is changed, leading to insensitive
sensitization and a strong motivation for drug use.192 Specifically, Robbins’
research describes:
“evidence that the switch from controlled to compulsive drug
seeking represents a transition at the neural level from prefrontal
cortical to striatal control over drug-seeking and drug-taking
behaviours as well as a progression from ventral to more dorsal
domains of the striatum, mediated by its serially interconnecting
dopaminergic circuitry. These neural transitions depend upon the
neuroplasticity induced by chronic self-administration of drugs in
both cortical and striatal structures, including long-lasting changes
that are the consequence of toxic drug effects.”193
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There is a substantial literature documenting reduced white matter
and damaged myelin in the brains of people with OUD,194 as well as deficits
in blood-oxygenated level responses (BOLD) evidenced on functional
magnetic resonance imaging. People with SUD have “showed less
activation in the frontal lobe than healthy subjects during the cocaine cue
tapes, suggesting that their ability to control their cue responses was
inhibited.”195 In a different study, researchers found that chronic cocaine
abusers had abnormally low levels of activity in midline areas of the
anterior cingulate that are crucial for cognitive and behavioral control.196
More recent and sophisticated methods have documented impaired
expression of genes related to the formation of blood cells and Tumor
Necrosis Factor (TNFα) signaling in the peripheral blood of individuals
with OUD.197 Tumor Necrosis Factor is an inflammatory cytokine that been
considered as an anti-cancer agent. Reduced expression suggests reduced
immune function in people with OUD. These researchers also found upregulation of mitochondrial genes and splicing related genes, which are
critical for generating different functional transcripts of the same gene.198
These are biomarkers of physical dependence on heroin, and the biomarkers
overlap with impairment seen in people with other neurodegenerative
disorders.199
While none of what I outlined above is controversial, some still
argue that addiction is not a biological or brain disease. The main reasons
given are 1) that the first decisions to use drugs are largely voluntary, and 2)
not everyone who uses drugs will ultimately become addicted. However,
this fails to recognize the importance of biological and environmental risk
factors in disease. Just as many people smoke who do not develop lung
cancer, or many people eat too many carbohydrates do not develop diabetes,
not everyone who uses drugs will develop physical dependence and
addiction. The differing results can be explained in part by our unique
genetic predisposition to SUD.
194
Mei Zhu, et al., Heroin Abuse Results in Shifted RNA Expression to Neurodegenerative Diseases
and Attenuation of TNF gamma Signaling Pathway, 8 SCIENTIFIC REPORTS 1, 5 (2018)
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JOANNA FOWLER, ET AL., IMAGING THE ADDICTED HUMAN BRAIN, 3 Sci. Pract. Perspect. 4-16 (2007)
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197
See, ThermoFisher Scientific, TNF Signaling Pathway, available online
https://www.thermofisher.com/us/en/home/life-science/antibodies/antibodies-learningcenter/antibodies-resource-library/cell-signaling-pathways/tnf-signaling-pathway.html
198
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and Attenuation of TNF gamma Signaling Pathway, 8 SCIENTIFIC REPORTS 1, 8 (2018) This analysis
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2. It is Not Just that Addiction Changes the Brain, Our Brains Can
Predispose Us to Addiction
There is no magic dose or duration of opioid use that will
predictably result in SUD. This is because not everyone is born with the
same neuro-genetic risk factors, and not everyone experiences the same
levels of childhood trauma or stress. Addiction has both genetic and
environmental influences, similar to many other complex and chronic
diseases.200 The genetic contribution to SUD is substantial, and accounts for
somewhere between 40 and 50% of the risk associated with addiction.201
Clinical studies have shown that the heritability rates of opioid addiction are
“similar to those of diabetes, asthma, and hypertension.”202 Additionally,
because of the “enhanced neuroplasticity of their brains and their
underdeveloped frontal cortex, which is necessary for self-control,”
adolescents are at an increased risk of developing SUD.203
There are many ways we can learn about the genetic contributions to
traits. A conventional method looks to family and twin epidemiological
studies, where we expect to see higher rates of addiction in homozygotic
twins than in heterozygous twins, and more in both than we see in siblings.
These studies show heritability estimates ranging from 30-60%.204 The
variation is large because some genetic variants are common to all
addictions and some affect risk to only a particular drug. 205 For example,
while twin studies show that SUD risk is shared among multiple classes of
drugs, some genetic risk is specific to a class of drugs, such as opiates. 206
Further, each stage of SUD will be impacted differently by genetics and the
environment. The transitions from initiation of drug use to routine drug use,
to physical dependence and even relapse may be driven by different genetic
factors, as they involve different physiological processes. 207
200
Kenneth Blum, et al., Genetic Addiction Risk Score (GARS), a predictor of vulnerability to opioid
dependence, 10 FRONT. IN BIOSCIENCES 175, 177 (2018).
201
Nora D. Volkow and A. Thomas McLellan, Opioid Abuse in Chronic Pain — Misconceptions and
Mitigation Strategies 374 NEW ENGL. J. MED. 1253, 1257 (2016); Volkow & Boyle, 175 Am. J.
Psychiat. 729 (2018) “Genetic Factors Account for Roughly 50% of the Risk of Addiction.”
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In addition to twin studies, researchers are using several novel
techniques to discover the patchwork of genes involved in addiction
generally, and OUD in particular. In the early 1970s, there was a “gamechanging” discovery that opiate drugs bind to receptors in the brain,
commandeering the endogenous internal system for reducing pain. There
are three G protein-coupled receptors (GPCRs) in the opioid system, known
as mu-, delta- and kappa-opioid receptors (MORs, DORs and KORs,
respectively). Under normal conditions, these receptors are stimulated by
endogenous opioid peptides, such as β-endorphin, enkephalins and
dynorphins, that may be triggered in response to physical exertion or pain.
However, when someone takes illicit drugs like heroin or pain medications
like hydrocodone, these drugs easily bind to the same mu-opioid receptors,
triggering a cascade of pain relief, pleasure, and dependence.
Recent research into the varying roles of the opioid receptors have
yielded new insights into their crucial roles in regulating the opponentprocesses of pain and pain relief. Opioid receptors play a role in each of the
three steps of SUD. Activation of the MOR during intoxication triggers
pleasure, or what was referred to as the a-process. Repeated MOR
activation leads to reduced drug reward (tolerance) and dependence or
withdrawal symptoms. KORs trigger the b-process of dysphoria through
dynorphin, which characterizes withdrawal and abstinence. 208 Stress and
drug abuse both enhance KOR–dynorphin signaling209. The DOR regulates
reinforcement learning and memory, while also reducing anxiety and
depressive states. 210 In the relapse stage, evidence supports a role for DORs
in context learning and memory for drug cues, like drug paraphernalia or
drug-using friends.211 All three opioid receptors likely influence the
preoccupation and craving state, and are implicated in drug-biased
motivation, habit formation and loss of inhibitory control. 212 Support for
these roles comes from locations in the mouse brain with high receptor
density, but these aspects are less well-characterized in the human brain.213
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Brain areas associated with planning such as the prefrontal cortex, have moderate density of all
types of receptors. MORs in the VTA trigger release of dopamine, projecting to the nuclueus
accumbens, which has a high density of MOR receptors and KOR receptors. The nucleus accumbens
has a large role in reward-learning and registering the salience of drugs during intoxication. The
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Given these unique receptor properties, targeting specific opioid
receptors, by blocking KOR and activating DOR, is a promising target for
the treatment of addiction, and other disorders like depression that stem
from low reward or high-aversion states. Interestingly, when researchers
deleted the OPRM1 gene in mice, this “simultaneously eliminated the
analgesic, rewarding and dependence-inducing effects of morphine,
demonstrating that the MOR is the sole responsible receptor for both the
therapeutic and the adverse actions of morphine.”214 Mutations in this
receptor gene have been repeatedly associated with increased addiction
risk.215 Recent research suggests there is substantial overlap between the
genetic correlates of opioid addiction and pain sensitivity,216 with one team
positing that mutations in the mu-opioid receptors might actually be the
drivers of not just OUD, but other forms of SUD.217
Of course, there are different pathways to addiction. There is no
“one gene” for addiction risk. Despite the significant role of mutations in
the opioid receptors, mutations in other genes also contribute to addiction
risk. Genome-wide association studies (GWAS) have found significant
associations between mutations linked with potassium and calcium
signaling networks in the brain, and developing OUD.218 These results were
most profound in the African-American subgroup sample. 219 Glutamate, an
excitatory neurotransmitter, also plays a large role in addiction. The Nmethyl-d-aspartate (NMDA) glutamate receptor gene GLUN3A has been
shown to serve an important role in the development of addiction.220

amygdala likewise has a high density of MOR, and to a lesser extent, KOR receptors. The MOR
receptors in the amygdala promote pleasure, while the KOR receptors in the amgydala promote
anxiety. The hippocampus has a high density of MOR and KOR receptors, and is critical in memory
formation. See, Emmanuel Darcq and Brigitte Lina Kieffer, Opioid Receptors as “Drivers” of the
Onset, Progression, and Maintenance of Addiction, 19 NATURE REVIEWS NEUROSCi 499, 504 (2018)
214
Emmanuel Darcq and Brigitte Lina Kieffer, Opioid Receptors as “Drivers” of the Onset,
Progression, and Maintenance of Addiction, 19 NATURE REVIEWS NEUROSCi 499, 499 (2018)
215
Specifially, mutations on the OPRM1; OPRK1; OPRD1; PDYN; POMC; PENK receptor genes
have all been associated with increased risk of OUD. See, Kenneth Blum, et al., Genetic Addiction
Risk Score (GARS), a predictor of vulnerability to opioid dependence, 10 FRONT. IN BIOSCIENCES
175, 179 (2018).
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“The[se] genes involved in the addictive process can also be indicative of which genes are
engaged in pain mechanisms, pain sensitivity, and opiate addiction.” See, Kenneth Blum, et al.,
Genetic Addiction Risk Score (GARS), a predictor of vulnerability to opioid dependence, 10 FRONT.
IN BIOSCIENCES 175, 179 (2018)
217
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218
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Associations Mapped to Calcium and Potassium Pathways, 76 BIOL. PSYCH. 66, 66 (2014)
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Mutations on the GABA receptors have also been implicated, through
microarray, single-gene strategies, and genome-wide association studies.221
Due to the heavy involvement of dopaminergic pathways, mutations
on the dopamine receptor gene, D2, (located on chromosome 11 q22-q23)
have been extensively studied.222 Hundreds of studies have connected the
DRD2 gene in particular to OUD, suggesting low baseline levels of
hedonia and higher levels of anxiety as the behavioral phenotypes that give
rise to abuse.223 One lab has determined that the DRD2 A1 mutation has a
Positive Predictive Value (PPV) of 74%, indicating “that if a child is born
with this polymorphism they have a very high risk of becoming addicted to
either drugs, food, or aberrant behaviors at some point in their future.”224
In addition to the substantial and growing evidence of genetic
contributions to SUD, there is extensive research on the genetic risk for
behavioral endophenotypes of addiction. For example, traits such as
impulsivity, risk-taking and depression may contribute to the initiation of
drug use as well as the transitions from initial use to regular use to
addiction. As Robbins’ team has documented, individuals with hypodominergic systems (reduced endogenous dopamine release) and impaired
inhibitory control in the cerebral cortex are vulnerable to developing
SUD.225 Impulsive rats are not only much more likely to escalate selfadministration of cocaine but also much more likely to relapse to a drugseeking habit after some period of abstinence.226 People with depression227
and anxiety are also at increased risk of SUD. Each of these personality
dimensions, or endophenotypes, has its own complex genetic basis.228
Given that a significant risk factor for developing addiction lies in
our genes, one lab has gone so far as to create a Genetic addiction risk score
221
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(GARS).TM229 It is hoped that these risk scores, calculated based on the
presence of multiple mutations, can better predict the development of SUD,
and relapse. These tools may one day be used in the clinic, as a screening
tool for prescribing addictive medications like opioids, or to help prevent
problem drug-use before it rises to the level of dependence.
3. Genetic Explanations Might Reduce Responsibility, But Do Not Reduce
Stigma on Their Own
We now know that addiction is caused in large part by our genes,
which we have no control over and we cannot change. Given this, some
have suggested that, “questions about right or wrong-doing seem to be illposed.”230 This is because we typically blame people for things that are
under their control, and for which they make a voluntary decision to do.231
It is much harder to justify blaming someone for their behavior, once we
know that for genetic reasons, it is considerably more difficult for them to
conform their behavior to a particular standard. This presents some
challenges to the pure moral choice model of addiction, as there are clear
inequities in our inherent abilities to refrain from becoming dependent.
Do we blame people for developing PTSD or Alzheimer’s? And
even if we continue to blame someone for developing lung cancer or
diabetes, because these too are caused in part by behavioral choices, we still
view these diseases as a medical problem deserving of a medical treatment.
It would be far too ambitious to expect the IDM to erase stigma completely.
Rather, the IDM model will be more effective at helping policymakers and
the public understand that some people are much more vulnerable to
addiction, due to their neuro-genetics. This would hopefully lead to policies
that emphasize treatment, prevention, and harm-reduction, rather than
criminalization and social isolation. Addiction is a disease, we should treat
it like one. While we can and must address social and personal
determinants, we must initially focus primarily on the primary determinants
of health, as we would with any other disease.
Proponents of the brain disease model have argued that a
neuroscience perspective reduces attributions of free will, (namely volition
229
See, Kenneth Blum, et al., Genetic Addiction Risk Score (GARS), a predictor of vulnerability
to opioid dependence, 10 FRONT. IN BIOSCIENCES 175, 179 (2018).
230
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231
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agreement about the actual existence of an effect of neuroscience information on belief in free will;
otherwise, the debate would be moot.” Eric Racine, Sebastian Sattler, and Alice Escande, Free Will
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and responsibility) because it “relocates the disorder to the brain, rather than
to the person.”232 However, as mentioned infra at [x], the disease need not
be “located” in the brain to be an ordinary disease worthy of treatment. In
keeping with this general idea, the National Alliance on Mental Illness
(NAMI) argued that once the public understood mental illnesses to be a
“real,” disease, and with a similar biological etiology to cancer or diabetes,
prejudice and discrimination would fade.233 Their campaign, “A Disease
Like Any Other,” focused on educating people about the brain disease
model of mental illnesses such as addiction. National surveys have
documented the success of their educational messaging, with mental health
literacy increasing significantly in recent decades.234 Many more Americans
now appreciate that substance abuse has a large hereditary and
environmental component, and is not entirely a disease of the weakwilled.235
However, importantly, so far this has not lead to universal, reduced
attributions of stigma.236 Indeed, attributing addiction to genetic factors,
may have caused some backlash.237 This may be because genetic causes
appear immutable and with lasting impact for generations.238
Two meta-analyses, looking at the effect of the brain disease model
on attributions of responsibility and stigma yielded consistent patterns.
When the team reviewed the experimental studies, they indicated that
neuro-genetic explanations “reduced blame, increased perceived
dangerousness and prognostic pessimism, and had no effect on social
distance.”239 Their review of the correlational studies found that “people
who endorse biogenetic explanations tend to blame affected persons less for
their problems, but perceive them as more dangerous and desire greater
232
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social distance from them.”240 No correlational studies addressed prognostic
pessimism. These findings led the researchers to propose the “mixed
blessings” model of stigma. Fueled in part by a belief that a “deep seated,
hidden essence is shared by all members of a category” the brain disease
model reduced individual control and therefore moral responsibility, but
increased genetic essentialist thinking, or that affected people have
predictable traits that can be explained almost entirely by their genes. 241
Essentialist thinking leads to fear, social distance, and pessimism about
treatment, as the genes are given a powerful role in determining behavior.242
When we think of people as having a difference, that is immutable, can be
labeled, and that leads to antisocial behavior, this can engender the very
stigma and dehumanization we sought to avoid.243
In contrast, people may think of neurobiological causes of disorders
as less binary than genetic causes, as brains are less static, and more plastic.
Genes may be thought of as deep, ultimate causes, with the brain operating
at a more intermediate level of translation244. A study focusing more on the
neuroscientific explanations of mental illness generally, found similar
results to the genetic studies.245 However, as an author of one of the studies
included in the analysis, the authors could not conclude that our study
isolated neuroscientific explanations, as our causal model included genetics
and neuroscience explanations for the aberrant behavior.246 Nonetheless, the
authors concluded that it could be that people misunderstand how the brain
works and think of it deterministically like genes. Or, it could be that
understanding someone as having reduced behavioral control makes them
more unpredictable, and therefore, scarier and deserving of punishment.
A recent experiment sought to explore the impact of neuro-genetic
causal models of addiction on attributions of free will and responsibility.
The researchers showed respondents text and a neuro-image (which
unfortunately explained the neurobiological basis of addiction by
240
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referencing reduced dopamine receptors in people who have SUD, which
could be an effect of the disorder rather than a cause), and compared this
with a control group. The respondents were asked to indicate the extent to
which they agreed with statements about cocaine addicts’ and alcoholics’
diminished free will.247 The findings were modest, but found attributions of
volition were somewhat reduced for the cocaine subsample, when
respondents viewed the textual and neuro-image explanations together, but
there was no effect when respondents viewed the text or neuro-image alone,
or when the information applied to alcoholics.248 However, respondent
characteristics such as education and self-reported knowledge of
neuroscience were associated with lower attributions of responsibility for
both substances, and education was associated with lower attribution of
volition for the alcohol sub-sample.249
In summary, the brain disease model has not been an unmitigated
success. There are risks associated with explaining addiction in terms of
neuroscience, as “descriptive neuroscience concepts are inseparable from
historical attitudes and intuitions towards addiction and addicted persons.
Placing emphasis on the diseased brain may foster unintended harm by
paradoxically increasing social distance towards the vulnerable group the
term is intended to benefit.”250 However, it has moved the needle on
pushing the public to support more treatment. While endorsements of a
genetic cause of addiction has led to greater support for seeking treatment
from psychiatrists, hospitals, and medications, in some cases it has also
provoked greater cynicism about the potential efficacy of treatment.251
Clearly, the brain disease model of addiction, relying solely on neurogenetics, cannot work alone.
F. We Must Develop a New Public Health Campaign Based on
the IDM
The brain disease model of addiction, with a heavy emphasis on the
idea that the brain is “hijacked” and the genes are determined, has not
247
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worked so far to reduce stigma and increase treatment. What is needed is a
more nuanced model, such as the IDM, that can confront the reality of
addiction as a disease, with neuro-genetic and environmental risk factors
which exist on a continuum, and for which there are successful treatments.
Recent data from public health suggests that when combined in this way,
the neuro-genetic evidence can work to reduce stigma. Rather than seeing
the brain as hijacked and controlling the disease process entirely, the IDM
can explain important causes of addiction as neuro-genetic, while
recognizing the importance of environmental risk and personal choice. We
need to stop feeding the false dichotomy of disease or choice, with a more
nuanced public health campaign that is experimentally tested and uses
destigmatizing language and images.252
The false dichotomy has led some physicians to flip back and forth
between the moral choice and disease model, when explaining addiction to
their patients.253 Studies demonstrate that physicians feel the need to switch
back and forth between “their deployment of disease, moral and social
models depending on how they wish to frame a client’s sense of
responsibility for the problem and the solution...” 254 Rather than asking
physicians to be agile, and selectively employ different models of addiction,
the IDM allows them to speak with one consistent message.255 There are not
competing models of addiction—there is one model that accommodates
developments in neuro-genetics and psychology, and reflects the reality of
people living with addiction, that it involves some level of individual
choice, and leads to antisocial behaviors that we would like to see treated.
The only reason this simple resolution has been so hard to grasp in the field
of addiction, and not elsewhere, is the pervasiveness of the stigma
surrounding the disease.
a. Part 1 of the Public Health Campaign: Addiction Risk Exists on A
Continuum, And Presents as a Neurobiological Disease
So far, the “dialogue around opioids has been dominated by several
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approaches that on their own are inadequate or harmful.”256 To mitigate
stigma, we must develop a comprehensive public health campaign that is
based on a model like the IDM. This campaign should rely on individual
stories as well as data, to explain the simple facts that anyone—no matter
their education, class, or race—can develop SUD.257 Using the
neurobiological evidence for SUD, the public health message must also
include information that once someone is addicted, their voluntary choices
are highly constrained because of the disease. The specific messaging of the
campaign should be created after experimental testing.258 However, recent
studies from public health make it clear that certain types of messages will
be more successful than others to reduce stigma and encourage treatment.
The first way we can reduce the “othering” of people with addiction
is to emphasize that the disease, and its risk factors, exist on a continuum.
While some were concerned that a model of addiction that focused on the
brain would encourage an “Us vs. Them” dynamic, (the normal and the
diseased), we can diminish this effect by instead by focusing on the idea
that risk factors are not categorical, and each of us has varying degrees of
genetic risk.259
People with SUD are not categorically different from us. Rather,
they have underlying genetic and environmental vulnerabilities, and these
risks are present to a degree in each of us. With the right combination of
factors, any one of us can be affected. Addiction is not a disease of the weak
or immoral. Public health campaigns should emphasize that there is an
underlying vulnerability in each of us that we did not cause and cannot
control. As there are different pathways to addiction, some of us are at
greater risk due to our genes for processing opioids, genes for processing
dopamine, or genes for memory encoding, etc. If you prefer to speak in
terms of endophenotypes, some of us are at greater risk due to our anxiety,
depression, or impulsivity.260 This is consistent with the Research Domain
Criteria put forward by the National Institutes of Health, which advocates
256
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for understanding mental illness as a constellation of component
psychological and neurobiological processes, which exist on a continuum.
Each mental illness can be conceived of as a natural process, such as reward
learning or fear processing, that has become extremely disordered. But we
all have varying levels of disorder in different domains.
This non-categorical way of thinking is in keeping with the new
Diagnostic and Statistical Manual (DSM-V) diagnostic criteria for SUD,
which recognizes that SUD exists on a continuum.261 This is not only the
right way of thinking about SUD, in terms of our underlying neuro-genetic
risk factors. It will also reduce the extent to which we think of people with
SUD as the categorical “other,” which can lead to stigma and
dehumanization.
Viewing SUD as existing on a continuum can also help people get
treatment sooner. It is difficult to remove the stigma from addiction because
people conflate severe SUD with all forms of SUD.262 People do not get
treatment because they do not want to accept the label of “addict,” because
in their minds there is only recreational drug us, and extreme, full-blown
“addiction.” There is nothing in the middle. Getting people to access
treatment when the disease is in its modest or early stages will lead to much
better recovery outcomes. Just as lung cancer patients have much better
prognoses if the cancer is caught at Stage 2 rather than at Stage 4, so too do
patients with modest SUD fair better than people with severe SUD.
b. Part 2 of the Public Health Campaign: Addiction is Treatable
When reporting on addiction, journalists often focus on specific
individuals, even when the highlighted individual is atypical.263 The public
then extrapolates from this narrative, which impacts how they view the
entire affected population.264 Most U.S. news media coverage of opioid
analgesic abuse from 1998 to 2012 focused on illegal drug dealing and
over-prescribing of pain medications by physicians.265 Among the news
stories that mentioned a solution, law enforcement arrests and punishment
261
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were mentioned most frequently, at 64% of news stories, with only 3%
mentioning expanding substance use treatment and less than 1% suggesting
harm-reduction policies.266 In keeping with the moral choice model of
addiction, news stories emphasized OUD as a criminal issue, rather than as
a treatable medical condition.267 This has exacerbated stigma, as people
think of SUD as an untreatable condition. This may also be why 65% of
Americans thought people with untreated alcoholism were likely to be
violent, and 87% thought someone with untreated cocaine dependence were
likely to be violent, even though they are much more likely to injure
themselves.268 Stories that depict addicts as dangerous are more likely to
lead to stigmatized views and a sense that these people need to be punished.
Newsflash: most people who are treated for SUD with evidencebased treatments achieve remission.269 This fact needs to be much more
widely known. We need to fund public health campaigns that emphasize
treatment options, and the efficacy of those options.270 A few recent studies
demonstrate that when news media mentions treatability, this is positively
correlated with endorsing mental health treatment policies.271 Further, when
drug addiction is portrayed as a treatable health condition, this reduces
desire for social distance, improves belief in the effectiveness of treatment,
and lessens willingness to discriminate against people with SUD.272
Specifically, as compared to respondents who read vignettes about
untreated OUD, when respondents read vignettes about individuals with
SUD who had been successfully treated, this group was much less likely to
reject the prospect of working with someone with addiction or having them
marry in to the family.273 Reading about individuals in recovery also made
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respondents more likely to believe treatment can effectively control
symptoms, though this particular study did not find support for increased
spending on addiction treatment, as older studies have. 274
IV.

CONCLUSION

The IDM I propose recognizes that SUD is not a moral failing, but a
complex and chronic disease, with environmental and neuro-genetic risk
factors. Rather than furthering the false dichotomy between moral choice
and biological disease, the IDM places addiction on equal footing with
other complex and chronic diseases, such as lung cancer or diabetes, each of
which has environmental and genetic risk factors. Through the IDM, the
policy and public health emphasis can be properly placed on treatment.
Given that addiction is a medical problem, our primary response should be
medical, not criminal—and not even sociological. While we should not
ignore important social determinants of health, such as childhood trauma,
access to safe housing and jobs, and criminal justice reform, these should be
secondary concerns. Addiction is a disease, but due to rampant
dehumanization of people with addiction, we have failed to see it as such.
The stigma surrounding people with SUD is rampant, and will take
concerted effort to mitigate. By engaging in a massive public health
campaign that emphasizes that addiction risk is neuro-genetic and exists on
a continuum, that once addiction takes hold voluntary choices related to
drug use are constrained, and that treatment can be quite effective, we can
start telling a different, and more hopeful story about recovery. As stigma
in its many forms is a major obstacle in the treatment of addiction,
mitigating stigma will have a cascade of positive effects. Reducing stigma
will encourage people to seek treatment, will help ensure that the treatment
that they receive is evidence-based and compassionate, and will reduce the
unfair discrimination and criminalization that people with SUD experience.
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